Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06607471

Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.

Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are "overlap" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the "undefined" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.

To the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and "inflammatory" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:

1. Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied. 2. Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.

Based on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-ischemic Cardiomyopathy Anderson-Fabry Disease Aortic Stenosis, Subvalvular Aortic Valve Disease Aortic Valve Stenosis Arrhythmias, Cardiac Arrhythmic and Inflammatory Non-ischemic Cardiomyopathy Arrhythmogenic Cardiomyopathy (AC, ARVD/C) Arrhythmogenic Mitral Valve Prolapse Arrhythmogenic Right Ventricular Dysplasia Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Cardiac Complexes, Premature Cardiac Conduction System Disease Cardiomegaly Cardiomyopathies Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiovascular Abnormalities Cardiovascular Diseases Central Nervous System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Death Death, Sudden Death, Sudden, Cardiac Dilated Cardiomyopathy (DCM) Fabry Disease Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Genetic Diseases, X-Linked Heart Arrest Heart Defects, Congenital Heart Diseases Heart Valve Diseases Hypertrophic Cardiomyopathy (HCM) Inflammatory (Non-Arrhythmic) Non-ischemic Cardiomyopathy Laminopathies Left Ventricular Noncompaction Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipidoses Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Major Ventricular Arrhythmias, I.e. Sustained Ventricular Tachycardia, Ventricular Fibrillation, or Appropriate Therapy of Cardiac Device (defibrillators) Metabolic Diseases Metabolism, Inborn Errors Myocarditis Nervous System Diseases Nonischemic Cardiomyopathy Sensu Strictu (Non-inflammatory, Non-arrhythmic) Nutritional and Metabolic Diseases Overlapping Phenotype Pathologic Processes Pathological Conditions, Signs and Symptoms Peripartum Cardiomyopathy Pregnancy Complications Pregnancy Complications, Cardiovascular Restrictive Cardiomyopathy Sphingolipidoses Tachycardia Tachycardia, Ventricular Undefined Phenotypes Urogenital Diseases Vascular Diseases Ventricular Fibrillation Ventricular Premature Complexes

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This study aims to collect clinical data of both retrospective and prospective patients with suspected or proven NICMs in a registry. The scope of the registry is to answer multiple unsolved questions in the field of AINICM as described below:

  • Improving the diagnostic workup. While genetic test and cardiac magnetic resonance (CMR) constitute the gold standard dagnostic techniques for NICM, it is known that; A) the yield of genetic test is low in NICM; B) the diagnostic performance of CMR may be limited in AINICM, because of cardiac device-related artifacts and/or irregular heartbeat. In this setting, alternative diagnostic techniques, namely computed tomography (CT) scan, positron emission tomography (PET), electroanatomical map (EAM) and endomyocardial biopsy (EMB) may be clinically helpful, as recommended for the investigation of many arrhythmogenic substrates.
  • Identifying disease-specific signatures. Genotype-phenoype associations are expected to benefit from a multimodal and multiparametric approach, in order to allow etiology-specific features in AINICM. Most of the current signatures are limited to combined genotype-CMR studies. Signatures would likely benefit from implementing additional parameters, including arrhythmia features and myocadial inflammatory status.
  • Working our models for risk prediction. Outcomes and arrhythmic risk stratification remain uncertain for most NICM. Based on an advanced multimodal workup, multiparametric risk scores may be created and subsequenlty validated, in order to predict the arrhythmic risk of specific cardiomyopathies. This would improve and refine the scores currently available for a limited number of NICM, such as HCM, classic right ventricular ACM, or cardiomyopathies secondary to LMNA gene mutation. Parameters from clinical arrhythmology and cardiac electrophysiology, as well as those related to inflammation, may improve the current status of the art about risk prediction.
  • Tailoring treatment strategies. A multimodal (i.e. by use of multiple diagnostic techniques) and multidisciplinary (i.e. by means of a team of cardiac electrophysiologists, cardiologists, radiologists, geneticists, immunologists, cardiac pathologists, pediatricians) model may help improving therapeutic strategies in AINICM, as already demonstrated in myocarditis. In detail, treatment options will include guideline-directed cardiological treatment, implantable cardiac devices, antiarrhythmic drugs, immunomodulating agents and catheter ablation of arrhythmias. In this setting, the coordinating center is an internationally recognized third-level referral center for the management of ventricular arrhythmias, and already has advanced facilities, including a dedicated multidisciplinary disease unit for myocarditis and inflammatory cardiomyopathies. In this setting, preliminary evidence suggests a potential benefit from targeting M-Infl even in NICM and AINICM.
  • Allowing direct comparison among specific NICM subgroups. Extensive inclusion criteria, allowing the entry of all NICM in a common registry with homogeneous variables would enable the direct comparison of different AINICM types, by means of multiparametric and multimodal characterization, for the first time including both the electrophysiological and inflammatory viewpoints. This is expected to significantly advance the status of knowledge in the field of NICM.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.
  • Clinical suspicion of NICM, and/or proven diagnosis of any NICM and/or genotype consistent with any NICM.

NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

Exclusion criteria

  • Absent informed consent.
  • Proven diagnosis of cardiac disease alternative to NICM.
  • Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.
  • For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.

Treatment and study plan

support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation

Other

Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Support treatment, cardiac medical treatment, aetiology-specific treatment

Other

Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Primary outcomes

  1. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  2. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  3. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  4. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  5. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  6. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  7. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  8. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  9. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  10. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  11. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  12. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  13. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  14. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  15. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  16. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  17. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  18. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  19. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  20. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  21. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  22. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  23. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  24. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  25. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  26. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  27. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  28. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  29. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  30. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  31. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  32. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  33. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  34. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  35. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  36. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  37. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  38. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  39. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  40. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  41. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  42. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  43. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  44. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  45. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  46. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  47. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  48. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  49. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  50. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  51. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  52. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  53. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  54. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  55. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  56. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  57. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  58. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  59. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  60. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  61. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  62. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  63. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  64. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  65. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  66. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  67. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  68. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  69. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  70. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  71. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  72. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  73. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  74. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  75. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  76. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  77. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  78. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  79. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  80. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  81. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  82. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  83. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  84. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  85. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  86. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  87. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  88. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  89. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  90. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  91. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  92. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes

    Time frame: At baseline

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  93. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes

    Time frame: At year 5

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  94. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes

    Time frame: At year 10

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  95. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes

    Time frame: At year 15

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  96. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes

    Time frame: At year 20

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  97. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes

    Time frame: At year 25

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  98. Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes

    Time frame: At year 30

    Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value

  99. Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  100. Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  101. Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  102. Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  103. Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  104. Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  105. Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  106. Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  107. Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  108. Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  109. Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  110. Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  111. Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  112. Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  113. Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  114. Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  115. Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  116. Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  117. Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  118. Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  119. Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  120. Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  121. Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  122. Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  123. Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  124. Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  125. Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  126. Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  127. Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  128. Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  129. Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  130. Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  131. Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  132. Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  133. Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  134. Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  135. Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  136. Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  137. Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  138. Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  139. Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  140. Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  141. Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  142. Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  143. Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  144. Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  145. Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  146. Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  147. Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  148. Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  149. Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  150. Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  151. Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  152. Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  153. Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  154. Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  155. Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  156. Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  157. Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  158. Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  159. Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  160. Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  161. Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  162. Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  163. Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  164. Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  165. Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  166. Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  167. Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  168. Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  169. Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  170. Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  171. Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  172. Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  173. Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  174. Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  175. Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  176. Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  177. Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  178. Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  179. Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  180. Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  181. Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  182. Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  183. Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  184. Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  185. Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  186. Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  187. Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  188. Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  189. Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  190. Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At baseline

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  191. Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 5

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  192. Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 10

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  193. Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 15

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  194. Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 20

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  195. Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 25

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  196. Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 30

    Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  197. Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  198. Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  199. Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  200. Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  201. Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  202. Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  203. Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  204. Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  205. Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  206. Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  207. Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  208. Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  209. Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  210. Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  211. Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  212. Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  213. Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  214. Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  215. Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  216. Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  217. Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  218. Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  219. Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  220. Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  221. Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  222. Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  223. Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  224. Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  225. Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  226. Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  227. Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  228. Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  229. Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  230. Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  231. Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  232. Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  233. Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  234. Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  235. Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  236. Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  237. Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  238. Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  239. Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  240. Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  241. Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  242. Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  243. Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  244. Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  245. Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  246. Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  247. Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  248. Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  249. Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  250. Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  251. Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  252. Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  253. Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  254. Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  255. Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  256. Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  257. Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  258. Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  259. Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  260. Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  261. Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  262. Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  263. Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  264. Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  265. Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  266. Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  267. Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  268. Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  269. Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  270. Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  271. Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  272. Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  273. Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  274. Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  275. Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  276. Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  277. Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  278. Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  279. Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  280. Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  281. Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  282. Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  283. Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  284. Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  285. Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  286. Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  287. Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  288. Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At baseline

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  289. Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 5

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  290. Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 10

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  291. Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 15

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  292. Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 20

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  293. Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 25

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  294. Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup

    Time frame: At year 30

    The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry

  295. Identification of DCM-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  296. Identification of DCM-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  297. Identification of DCM-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  298. Identification of DCM-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  299. Identification of DCM-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  300. Identification of DCM-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  301. Identification of DCM-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  302. Identification of HCM-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  303. Identification of HCM-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  304. Identification of HCM-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  305. Identification of HCM-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  306. Identification of HCM-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  307. Identification of HCM-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  308. Identification of HCM-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  309. Identification of RCM-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  310. Identification of RCM-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  311. Identification of RCM-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  312. Identification of RCM-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  313. Identification of RCM-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  314. Identification of RCM-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  315. Identification of RCM-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  316. Identification of ACM-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  317. Identification of ACM-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  318. Identification of ACM-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  319. Identification of ACM-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  320. Identification of ACM-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  321. Identification of ACM-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  322. Identification of ACM-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  323. Identification of LVNC-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  324. Identification of LVNC-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  325. Identification of LVNC-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  326. Identification of LVNC-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  327. Identification of LVNC-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  328. Identification of LVNC-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  329. Identification of LVNC-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  330. Identification of AMVP-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  331. Identification of AMVP-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  332. Identification of AMVP-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  333. Identification of AMVP-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  334. Identification of AMVP-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  335. Identification of AMVP-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  336. Identification of AMVP-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  337. Identification of PPCM-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  338. Identification of PPCM-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  339. Identification of PPCM-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  340. Identification of PPCM-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  341. Identification of PPCM-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  342. Identification of PPCM-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  343. Identification of PPCM-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  344. Identification of AFD-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  345. Identification of AFD-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  346. Identification of AFD-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  347. Identification of AFD-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  348. Identification of AFD-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  349. Identification of AFD-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  350. Identification of AFD-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  351. Identification of storage and dysmetabolic diseases-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  352. Identification of storage and dysmetabolic diseases-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  353. Identification of storage and dysmetabolic diseases-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  354. Identification of storage and dysmetabolic diseases-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  355. Identification of storage and dysmetabolic diseases-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  356. Identification of storage and dysmetabolic diseases-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  357. Identification of storage and dysmetabolic diseases-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  358. Identification of mitochondrial diseases-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  359. Identification of mitochondrial diseases-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  360. Identification of mitochondrial diseases-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  361. Identification of mitochondrial diseases-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  362. Identification of mitochondrial diseases-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  363. Identification of mitochondrial diseases-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  364. Identification of mitochondrial diseases-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  365. Identification of channelopathies with structural changes-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  366. Identification of channelopathies with structural changes-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  367. Identification of channelopathies with structural changes-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  368. Identification of channelopathies with structural changes-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  369. Identification of channelopathies with structural changes-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  370. Identification of channelopathies with structural changes-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  371. Identification of channelopathies with structural changes-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  372. Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  373. Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  374. Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  375. Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  376. Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  377. Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  378. Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  379. Identification of overlapping phenotypes-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  380. Identification of overlapping phenotypes-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  381. Identification of overlapping phenotypes-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  382. Identification of overlapping phenotypes-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  383. Identification of overlapping phenotypes-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  384. Identification of overlapping phenotypes-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  385. Identification of overlapping phenotypes-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  386. Identification of undefined phenotypes-specific signatures

    Time frame: At baseline

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  387. Identification of undefined phenotypes-specific signatures

    Time frame: At year 5

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  388. Identification of undefined phenotypes-specific signatures

    Time frame: At year 10

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  389. Identification of undefined phenotypes-specific signatures

    Time frame: At year 15

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  390. Identification of undefined phenotypes-specific signatures

    Time frame: At year 20

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  391. Identification of undefined phenotypes-specific signatures

    Time frame: At year 25

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  392. Identification of undefined phenotypes-specific signatures

    Time frame: At year 30

    Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.

  393. Differences in incidence of major events during follow-up in different NICMs

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  394. Differences in incidence of major events during follow-up in different NICMs

    Time frame: At year 5

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  395. Differences in incidence of major events during follow-up in different NICMs

    Time frame: At year 10

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  396. Differences in incidence of major events during follow-up in different NICMs

    Time frame: At year 15

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  397. Differences in incidence of major events during follow-up in different NICMs

    Time frame: At year 20

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  398. Differences in incidence of major events during follow-up in different NICMs

    Time frame: At year 25

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  399. Differences in incidence of major events during follow-up in different NICMs

    Time frame: At year 30

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  400. Occurrence of major cardiac events in DCM

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl.

  401. Occurrence of major cardiac events in DCM

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  402. Occurrence of major cardiac events in DCM

    Time frame: At 3 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  403. Occurrence of major cardiac events in DCM

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  404. Occurrence of major cardiac events in DCM

    Time frame: At 15 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  405. Occurrence of major cardiac events in DCM

    Time frame: At 20 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  406. Occurrence of major cardiac events in DCM

    Time frame: At 25 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  407. Occurrence of major cardiac events in DCM

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  408. Occurrence of major cardiac events in HCM

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  409. Occurrence of major cardiac events in HCM

    Time frame: At 3 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  410. Occurrence of major cardiac events in HCM

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  411. Occurrence of major cardiac events in HCM

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  412. Occurrence of major cardiac events in HCM

    Time frame: At 15 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  413. Occurrence of major cardiac events in HCM

    Time frame: At 20 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  414. Occurrence of major cardiac events in HCM

    Time frame: At 25 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  415. Occurrence of major cardiac events in HCM

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  416. Occurrence of major cardiac events in RCM

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  417. Occurrence of major cardiac events in RCM

    Time frame: At 3 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  418. Occurrence of major cardiac events in RCM

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  419. Occurrence of major cardiac events in RCM

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  420. Occurrence of major cardiac events in RCM

    Time frame: At 15 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  421. Occurrence of major cardiac events in RCM

    Time frame: At 20 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  422. Occurrence of major cardiac events in RCM

    Time frame: At 25 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  423. Occurrence of major cardiac events in RCM

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  424. Occurrence of major cardiac events in ACM

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  425. Occurrence of major cardiac events in ACM

    Time frame: At 3 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  426. Occurrence of major cardiac events in ACM

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  427. Occurrence of major cardiac events in ACM

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  428. Occurrence of major cardiac events in ACM

    Time frame: At 15 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  429. Occurrence of major cardiac events in ACM

    Time frame: At 20 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  430. Occurrence of major cardiac events in ACM

    Time frame: At 25 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  431. Occurrence of major cardiac events in ACM

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  432. Occurrence of major cardiac events in LVNC

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  433. Occurrence of major cardiac events in LVNC

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  434. Occurrence of major cardiac events in LVNC

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  435. Occurrence of major cardiac events in LVNC

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  436. Occurrence of major cardiac events in AMVP

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  437. Occurrence of major cardiac events in AMVP

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  438. Occurrence of major cardiac events in AMVP

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  439. Occurrence of major cardiac events in AMVP

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  440. Occurrence of major cardiac events in PPCM

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  441. Occurrence of major cardiac events in PPCM

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  442. Occurrence of major cardiac events in PPCM

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  443. Occurrence of major cardiac events in PPCM

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  444. Occurrence of major cardiac events in AFD

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  445. Occurrence of major cardiac events in AFD

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  446. Occurrence of major cardiac events in AFD

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  447. Occurrence of major cardiac events in AFD

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  448. Occurrence of major cardiac events in storage and dysmetabolic diseases

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  449. Occurrence of major cardiac events in storage and dysmetabolic diseases

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  450. Occurrence of major cardiac events in storage and dysmetabolic diseases

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  451. Occurrence of major cardiac events in storage and dysmetabolic diseases

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  452. Occurrence of major cardiac events in mitochondrial diseases

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  453. Occurrence of major cardiac events in mitochondrial diseases

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  454. Occurrence of major cardiac events in mitochondrial diseases

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  455. Occurrence of major cardiac events in mitochondrial diseases

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  456. Occurrence of major cardiac events in channelopathies with structural changeschannelopathies with structural changes

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  457. Occurrence of major cardiac events in channelopathies with structural changes

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  458. Occurrence of major cardiac events in channelopathies with structural changes

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  459. Occurrence of major cardiac events in channelopathies with structural changes

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  460. Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  461. Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  462. Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  463. Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  464. Occurrence of major cardiac events in overlapping phenotypes

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  465. Occurrence of major cardiac events in overlapping phenotypes

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  466. Occurrence of major cardiac events in overlapping phenotypes

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  467. Occurrence of major cardiac events in overlapping phenotypes

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  468. Occurrence of major cardiac events in undefined phenotypes

    Time frame: At 1 year

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  469. Occurrence of major cardiac events in undefined phenotypes

    Time frame: At 5 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  470. Occurrence of major cardiac events in undefined phenotypes

    Time frame: At 10 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  471. Occurrence of major cardiac events in undefined phenotypes

    Time frame: At 30 years

    all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

  472. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  473. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  474. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  475. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  476. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  477. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  478. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM

    Time frame: At 30years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  479. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  480. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  481. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  482. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  483. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  484. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  485. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  486. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  487. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  488. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  489. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  490. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  491. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  492. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  493. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  494. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  495. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  496. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  497. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  498. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  499. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  500. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  501. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  502. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  503. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  504. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  505. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  506. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  507. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  508. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  509. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  510. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  511. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  512. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  513. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  514. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  515. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  516. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  517. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  518. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  519. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  520. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  521. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  522. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  523. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  524. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  525. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  526. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  527. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  528. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  529. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  530. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  531. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  532. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  533. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  534. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  535. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  536. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  537. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  538. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  539. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  540. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  541. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  542. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  543. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  544. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  545. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  546. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  547. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  548. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  549. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  550. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  551. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  552. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  553. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  554. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  555. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  556. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  557. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  558. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  559. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  560. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  561. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  562. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  563. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes

    Time frame: At baseline

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  564. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes

    Time frame: At 5 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  565. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes

    Time frame: At 10 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  566. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes

    Time frame: At 15 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  567. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes

    Time frame: At 20 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  568. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes

    Time frame: At 25 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

  569. Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes

    Time frame: At 30 years

    Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination.

    Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.

Secondary outcomes

  1. Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM

    Time frame: At baseline

    Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  2. Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM

    Time frame: At 5 years

    Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  3. Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM

    Time frame: At 10 years

    Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  4. Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM

    Time frame: At 15 years

    Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  5. Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM

    Time frame: At 20 years

    Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  6. Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM

    Time frame: At 25 years

    Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  7. Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM

    Time frame: At 30 years

    Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICMs, which include but not limit to DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  8. Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM

    Time frame: At baseline

    presence; type; quantification; pattern

  9. Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM

    Time frame: At 5 years

    presence; type; quantification; pattern

  10. Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM

    Time frame: At 10 years

    presence; type; quantification; pattern

  11. Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM

    Time frame: At 15 years

    presence; type; quantification; pattern

  12. Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM

    Time frame: At 20 years

    presence; type; quantification; pattern

  13. Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM

    Time frame: At 25 years

    presence; type; quantification; pattern

  14. Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM

    Time frame: At 30 years

    presence; type; quantification; pattern

  15. Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM

    Time frame: At baseline

    presence; type; quantification; pattern

  16. Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM

    Time frame: At 5 years

    presence; type; quantification; pattern

  17. Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM

    Time frame: At 10 years

    presence; type; quantification; pattern

  18. Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM

    Time frame: At 15 years

    presence; type; quantification; pattern

  19. Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM

    Time frame: At 20 years

    presence; type; quantification; pattern

  20. Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM

    Time frame: At 25 years

    presence; type; quantification; pattern

  21. Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM

    Time frame: At 30 years

    presence; type; quantification; pattern

  22. Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM

    Time frame: At baseline

    presence; type; quantification; pattern

  23. Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM

    Time frame: At 5 years

    presence; type; quantification; pattern

  24. Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM

    Time frame: At 10 years

    presence; type; quantification; pattern

  25. Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM

    Time frame: At 15 years

    presence; type; quantification; pattern

  26. Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM

    Time frame: At 20 years

    presence; type; quantification; pattern

  27. Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM

    Time frame: At 25 years

    presence; type; quantification; pattern

  28. Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM

    Time frame: At 30 years

    presence; type; quantification; pattern

  29. Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM

    Time frame: At baseline

    presence; type; quantification; pattern

  30. Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM

    Time frame: At 5 years

    presence; type; quantification; pattern

  31. Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM

    Time frame: At 10 years

    presence; type; quantification; pattern

  32. Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM

    Time frame: At 15 years

    presence; type; quantification; pattern

  33. Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM

    Time frame: At 20 years

    presence; type; quantification; pattern

  34. Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM

    Time frame: At 25 years

    presence; type; quantification; pattern

  35. Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM

    Time frame: At 30 years

    presence; type; quantification; pattern

  36. Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC

    Time frame: At baseline

    presence; type; quantification; pattern

  37. Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC

    Time frame: At 5 years

    presence; type; quantification; pattern

  38. Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC

    Time frame: At 10 years

    presence; type; quantification; pattern

  39. Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC

    Time frame: At 15 years

    presence; type; quantification; pattern

  40. Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC

    Time frame: At 20 years

    presence; type; quantification; pattern

  41. Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC

    Time frame: At 25 years

    presence; type; quantification; pattern

  42. Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC

    Time frame: At 30 years

    presence; type; quantification; pattern

  43. Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP

    Time frame: At baseline

    presence; type; quantification; pattern

  44. Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP

    Time frame: At 5 years

    presence; type; quantification; pattern

  45. Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP

    Time frame: At 10 years

    presence; type; quantification; pattern

  46. Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP

    Time frame: At 15 years

    presence; type; quantification; pattern

  47. Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP

    Time frame: At 20 years

    presence; type; quantification; pattern

  48. Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP

    Time frame: At 25 years

    presence; type; quantification; pattern

  49. Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP

    Time frame: At 30 years

    presence; type; quantification; pattern

  50. Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM

    Time frame: At baseline

    presence; type; quantification; pattern

  51. Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM

    Time frame: At 5 years

    presence; type; quantification; pattern

  52. Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM

    Time frame: At 10 years

    presence; type; quantification; pattern

  53. Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM

    Time frame: At 15 years

    presence; type; quantification; pattern

  54. Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM

    Time frame: At 20 years

    presence; type; quantification; pattern

  55. Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM

    Time frame: At 25 years

    presence; type; quantification; pattern

  56. Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM

    Time frame: At 30 years

    presence; type; quantification; pattern

  57. Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases

    Time frame: At baseline

    presence; type; quantification; pattern

  58. Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases

    Time frame: At 5 years

    presence; type; quantification; pattern

  59. Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases

    Time frame: At 10 years

    presence; type; quantification; pattern

  60. Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases

    Time frame: At 15 years

    presence; type; quantification; pattern

  61. Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases

    Time frame: At 20 years

    presence; type; quantification; pattern

  62. Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases

    Time frame: At 25 years

    presence; type; quantification; pattern

  63. Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases

    Time frame: At 30 years

    presence; type; quantification; pattern

  64. Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases

    Time frame: At baseline

    presence; type; quantification; pattern

  65. Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases

    Time frame: At 5 years

    presence; type; quantification; pattern

  66. Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases

    Time frame: At 10 years

    presence; type; quantification; pattern

  67. Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases

    Time frame: At 15 years

    presence; type; quantification; pattern

  68. Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases

    Time frame: At 20 years

    presence; type; quantification; pattern

  69. Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases

    Time frame: At 25 years

    presence; type; quantification; pattern

  70. Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases

    Time frame: At 30 years

    presence; type; quantification; pattern

  71. Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes

    Time frame: At baseline

    presence; type; quantification; pattern

  72. Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes

    Time frame: At 5 years

    presence; type; quantification; pattern

  73. Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes

    Time frame: At 10 years

    presence; type; quantification; pattern

  74. Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes

    Time frame: At 15 years

    presence; type; quantification; pattern

  75. Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes

    Time frame: At 20 years

    presence; type; quantification; pattern

  76. Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes

    Time frame: At 25 years

    presence; type; quantification; pattern

  77. Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes

    Time frame: At 30 years

    presence; type; quantification; pattern

  78. Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

    presence; type; quantification; pattern

  79. Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

    presence; type; quantification; pattern

  80. Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

    presence; type; quantification; pattern

  81. Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

    presence; type; quantification; pattern

  82. Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

    presence; type; quantification; pattern

  83. Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

    presence; type; quantification; pattern

  84. Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

    presence; type; quantification; pattern

  85. Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes

    Time frame: At baseline

    presence; type; quantification; pattern

  86. Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes

    Time frame: At 5 years

    presence; type; quantification; pattern

  87. Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes

    Time frame: At 10 years

    presence; type; quantification; pattern

  88. Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes

    Time frame: At 15 years

    presence; type; quantification; pattern

  89. Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes

    Time frame: At 20 years

    presence; type; quantification; pattern

  90. Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes

    Time frame: At 25 years

    presence; type; quantification; pattern

  91. Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes

    Time frame: At 30 years

    presence; type; quantification; pattern

  92. Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes

    Time frame: At baseline

    presence; type; quantification; pattern

  93. Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes

    Time frame: At 5 years

    presence; type; quantification; pattern

  94. Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes

    Time frame: At 10 years

    presence; type; quantification; pattern

  95. Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes

    Time frame: At 15 years

    presence; type; quantification; pattern

  96. Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes

    Time frame: At 20 years

    presence; type; quantification; pattern

  97. Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes

    Time frame: At 25 years

    presence; type; quantification; pattern

  98. Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes

    Time frame: At 30 years

    presence; type; quantification; pattern

  99. Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  100. Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  101. Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  102. Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  103. Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  104. Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  105. Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  106. Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  107. Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  108. Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  109. Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  110. Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  111. Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  112. Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  113. Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  114. Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  115. Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  116. Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  117. Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  118. Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  119. Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  120. Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  121. Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  122. Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  123. Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  124. Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  125. Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  126. Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  127. Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  128. Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  129. Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  130. Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  131. Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  132. Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  133. Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  134. Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  135. Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  136. Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  137. Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  138. Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  139. Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  140. Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  141. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  142. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  143. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  144. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  145. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  146. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  147. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  148. Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  149. Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  150. Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  151. Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  152. Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  153. Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  154. Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  155. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  156. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  157. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  158. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  159. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  160. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  161. Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  162. Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  163. Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  164. Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  165. Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  166. Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  167. Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  168. Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  169. Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  170. Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  171. Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  172. Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  173. Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  174. Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  175. Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  176. Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  177. Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  178. Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  179. Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  180. Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  181. Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  182. Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  183. Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  184. Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  185. Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  186. Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  187. Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  188. Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  189. Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  190. Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  191. Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  192. Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  193. Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  194. Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  195. Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  196. Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  197. Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes

    Time frame: At baseline

    correlation between M-Infl and arrhythmia type and ECG features

  198. Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes

    Time frame: At 5 years

    correlation between M-Infl and arrhythmia type and ECG features

  199. Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes

    Time frame: At 10 years

    correlation between M-Infl and arrhythmia type and ECG features

  200. Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes

    Time frame: At 15 years

    correlation between M-Infl and arrhythmia type and ECG features

  201. Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes

    Time frame: At 20 years

    correlation between M-Infl and arrhythmia type and ECG features

  202. Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes

    Time frame: At 25 years

    correlation between M-Infl and arrhythmia type and ECG features

  203. Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes

    Time frame: At 30 years

    correlation between M-Infl and arrhythmia type and ECG features

  204. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge

  205. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge

  206. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge

  207. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge

  208. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge

  209. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge

  210. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, neuromuscular, mitochondrial, toxic, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge

  211. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate correlation between EMB sampling site and localization of substrate

  212. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  213. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  214. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  215. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  216. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  217. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  218. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  219. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  220. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  221. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  222. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  223. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  224. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  225. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  226. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  227. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  228. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  229. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  230. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  231. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  232. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  233. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  234. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  235. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  236. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  237. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  238. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  239. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  240. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  241. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  242. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  243. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  244. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  245. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  246. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  247. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  248. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  249. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  250. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  251. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  252. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  253. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  254. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  255. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  256. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  257. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  258. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  259. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  260. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  261. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  262. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  263. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  264. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  265. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  266. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  267. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  268. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  269. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  270. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  271. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  272. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  273. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  274. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  275. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  276. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  277. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  278. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  279. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  280. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  281. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  282. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  283. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  284. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  285. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  286. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  287. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  288. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes

    Time frame: At baseline

    correlation between EMB sampling site and localization of substrate

  289. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes

    Time frame: At 5 years

    correlation between EMB sampling site and localization of substrate

  290. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes

    Time frame: At 10 years

    correlation between EMB sampling site and localization of substrate

  291. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes

    Time frame: At 15 years

    correlation between EMB sampling site and localization of substrate

  292. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes

    Time frame: At 20 years

    correlation between EMB sampling site and localization of substrate

  293. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes

    Time frame: At 25 years

    correlation between EMB sampling site and localization of substrate

  294. Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes

    Time frame: At 30 years

    correlation between EMB sampling site and localization of substrate

  295. Diagnostic yield of EMB guided by electroanatomical map in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  296. Diagnostic yield of EMB guided by electroanatomical map in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  297. Diagnostic yield of EMB guided by electroanatomical map in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  298. Diagnostic yield of EMB guided by electroanatomical map in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  299. Diagnostic yield of EMB guided by electroanatomical map in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  300. Diagnostic yield of EMB guided by electroanatomical map in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  301. Diagnostic yield of EMB guided by electroanatomical map in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  302. Diagnostic yield of EMB guided by electroanatomical map in DCM

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  303. Diagnostic yield of EMB guided by electroanatomical map in DCM

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  304. Diagnostic yield of EMB guided by electroanatomical map in DCM

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  305. Diagnostic yield of EMB guided by electroanatomical map in DCM

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  306. Diagnostic yield of EMB guided by electroanatomical map in DCM

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  307. Diagnostic yield of EMB guided by electroanatomical map in DCM

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  308. Diagnostic yield of EMB guided by electroanatomical map in DCM

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  309. Diagnostic yield of EMB guided by electroanatomical map in HCM

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  310. Diagnostic yield of EMB guided by electroanatomical map in HCM

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  311. Diagnostic yield of EMB guided by electroanatomical map in HCM

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  312. Diagnostic yield of EMB guided by electroanatomical map in HCM

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  313. Diagnostic yield of EMB guided by electroanatomical map in HCM

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  314. Diagnostic yield of EMB guided by electroanatomical map in HCM

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  315. Diagnostic yield of EMB guided by electroanatomical map in HCM

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  316. Diagnostic yield of EMB guided by electroanatomical map in RCM

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  317. Diagnostic yield of EMB guided by electroanatomical map in RCM

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  318. Diagnostic yield of EMB guided by electroanatomical map in RCM

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  319. Diagnostic yield of EMB guided by electroanatomical map in RCM

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  320. Diagnostic yield of EMB guided by electroanatomical map in RCM

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  321. Diagnostic yield of EMB guided by electroanatomical map in RCM

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  322. Diagnostic yield of EMB guided by electroanatomical map in RCM

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  323. Diagnostic yield of EMB guided by electroanatomical map in ACM

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  324. Diagnostic yield of EMB guided by electroanatomical map in ACM

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  325. Diagnostic yield of EMB guided by electroanatomical map in ACM

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  326. Diagnostic yield of EMB guided by electroanatomical map in ACM

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  327. Diagnostic yield of EMB guided by electroanatomical map in ACM

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  328. Diagnostic yield of EMB guided by electroanatomical map in ACM

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  329. Diagnostic yield of EMB guided by electroanatomical map in ACM

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  330. Diagnostic yield of EMB guided by electroanatomical map in LVNC

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  331. Diagnostic yield of EMB guided by electroanatomical map in LVNC

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  332. Diagnostic yield of EMB guided by electroanatomical map in LVNC

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  333. Diagnostic yield of EMB guided by electroanatomical map in LVNC

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  334. Diagnostic yield of EMB guided by electroanatomical map in LVNC

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  335. Diagnostic yield of EMB guided by electroanatomical map in LVNC

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  336. Diagnostic yield of EMB guided by electroanatomical map in LVNC

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  337. Diagnostic yield of EMB guided by electroanatomical map in AMVP

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  338. Diagnostic yield of EMB guided by electroanatomical map in AMVP

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  339. Diagnostic yield of EMB guided by electroanatomical map in AMVP

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  340. Diagnostic yield of EMB guided by electroanatomical map in AMVP

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  341. Diagnostic yield of EMB guided by electroanatomical map in AMVP

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  342. Diagnostic yield of EMB guided by electroanatomical map in AMVP

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  343. Diagnostic yield of EMB guided by electroanatomical map in AMVP

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  344. Diagnostic yield of EMB guided by electroanatomical map in PPCM

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  345. Diagnostic yield of EMB guided by electroanatomical map in PPCM

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  346. Diagnostic yield of EMB guided by electroanatomical map in PPCM

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  347. Diagnostic yield of EMB guided by electroanatomical map in PPCM

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  348. Diagnostic yield of EMB guided by electroanatomical map in PPCM

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  349. Diagnostic yield of EMB guided by electroanatomical map in PPCM

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  350. Diagnostic yield of EMB guided by electroanatomical map in PPCM

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  351. Diagnostic yield of EMB guided by electroanatomical map in AFD

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  352. Diagnostic yield of EMB guided by electroanatomical map in AFD

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  353. Diagnostic yield of EMB guided by electroanatomical map in AFD

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  354. Diagnostic yield of EMB guided by electroanatomical map in AFD

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  355. Diagnostic yield of EMB guided by electroanatomical map in AFD

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  356. Diagnostic yield of EMB guided by electroanatomical map in AFD

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  357. Diagnostic yield of EMB guided by electroanatomical map in AFD

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  358. Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  359. Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  360. Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  361. Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  362. Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  363. Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  364. Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  365. Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes

    Time frame: At baseline

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  366. Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes

    Time frame: At 5 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  367. Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes

    Time frame: At 10 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  368. Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes

    Time frame: At 15 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  369. Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes

    Time frame: At 20 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  370. Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes

    Time frame: At 25 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  371. Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes

    Time frame: At 30 years

    Investestigating the role of EMB guided by electroanatomical map in diagnosis

  372. Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  373. Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  374. Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  375. Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  376. Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  377. Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  378. Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  379. Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  380. Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  381. Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  382. Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  383. Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  384. Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  385. Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  386. Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  387. Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  388. Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  389. Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  390. Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  391. Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  392. Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  393. Evaluation of healing timing of M-Infl in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  394. Evaluation of healing timing of M-Infl in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  395. Evaluation of healing timing of M-Infl in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  396. Evaluation of healing timing of M-Infl in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  397. Evaluation of healing timing of M-Infl in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  398. Evaluation of healing timing of M-Infl in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  399. Evaluation of healing timing of M-Infl in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  400. Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  401. Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  402. Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  403. Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  404. Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  405. Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  406. Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  407. Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU

    Time frame: At baseline

    The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.

    This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  408. Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU

    Time frame: At 5 years

    The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.

    This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  409. Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU

    Time frame: At 10 years

    The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.

    This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  410. Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU

    Time frame: At 15 years

    The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.

    This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  411. Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU

    Time frame: At 20 years

    The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.

    This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  412. Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU

    Time frame: At 25 years

    The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.

    This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  413. Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU

    Time frame: At 30 years

    The diagnostic exams mainly include EMB, CMR/CT scan/PET, echocardiogram, stress tests, blood exams, genetic/blood/tissue/cell/molecular/multiomic biomarkers.

    This analysis regards but not limits to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  414. Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  415. Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  416. Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  417. Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  418. Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  419. Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  420. Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  421. Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  422. Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  423. Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  424. Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  425. Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  426. Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  427. Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  428. Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  429. Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  430. Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  431. Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  432. Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  433. Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  434. Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  435. Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  436. Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  437. Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  438. Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  439. Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  440. Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  441. Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  442. Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  443. Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  444. Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  445. Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  446. Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  447. Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  448. Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  449. Evaluation of coronary microvascular disease in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  450. Evaluation of coronary microvascular disease in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  451. Evaluation of coronary microvascular disease in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  452. Evaluation of coronary microvascular disease in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  453. Evaluation of coronary microvascular disease in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  454. Evaluation of coronary microvascular disease in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  455. Evaluation of coronary microvascular disease in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  456. Assessment of myocardial ischemia in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  457. Assessment of myocardial ischemia in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  458. Assessment of myocardial ischemia in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  459. Assessment of myocardial ischemia in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  460. Assessment of myocardial ischemia in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  461. Assessment of myocardial ischemia in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  462. Assessment of myocardial ischemia in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  463. Assessment of autoimmunity in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  464. Assessment of autoimmunity in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  465. Assessment of autoimmunity in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  466. Assessment of autoimmunity in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  467. Assessment of autoimmunity in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  468. Assessment of autoimmunity in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  469. Assessment of autoimmunity in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  470. Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  471. Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  472. Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  473. Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  474. Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  475. Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  476. Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  477. Assessment of hemodynamic changes in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  478. Assessment of hemodynamic changes in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  479. Assessment of hemodynamic changes in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  480. Assessment of hemodynamic changes in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  481. Assessment of hemodynamic changes in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  482. Assessment of hemodynamic changes in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  483. Assessment of hemodynamic changes in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  484. Multimodal multiparametric imaging investigation of NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  485. Multimodal multiparametric imaging investigation of NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  486. Multimodal multiparametric imaging investigation of NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  487. Multimodal multiparametric imaging investigation of NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  488. Multimodal multiparametric imaging investigation of NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  489. Multimodal multiparametric imaging investigation of NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  490. Multimodal multiparametric imaging investigation of NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  491. Evaluation of differential diagnosis between NICMs and other cardiac diseases

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  492. Evaluation of differential diagnosis between NICMs and other cardiac diseases

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  493. Evaluation of differential diagnosis between NICMs and other cardiac diseases

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  494. Evaluation of differential diagnosis between NICMs and other cardiac diseases

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  495. Evaluation of differential diagnosis between NICMs and other cardiac diseases

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  496. Evaluation of differential diagnosis between NICMs and other cardiac diseases

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  497. Evaluation of differential diagnosis between NICMs and other cardiac diseases

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  498. Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  499. Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  500. Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  501. Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  502. Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  503. Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  504. Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  505. Analysis of correlation between local and systemic/peripheral inflammation in NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  506. Analysis of correlation between local and systemic/peripheral inflammation in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  507. Analysis of correlation between local and systemic/peripheral inflammation in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  508. Analysis of correlation between local and systemic/peripheral inflammation in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  509. Analysis of correlation between local and systemic/peripheral inflammation in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  510. Analysis of correlation between local and systemic/peripheral inflammation in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  511. Analysis of correlation between local and systemic/peripheral inflammation in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  512. Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  513. Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  514. Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  515. Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  516. Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  517. Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  518. Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  519. Investigation of infectious, toxicologic, and immunologic factors associated with NICMs

    Time frame: At baseline

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  520. Investigation of infectious, toxicologic, and immunologic factors associated with NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  521. Investigation of infectious, toxicologic, and immunologic factors associated with NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  522. Investigation of infectious, toxicologic, and immunologic factors associated with NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  523. Investigation of infectious, toxicologic, and immunologic factors associated with NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  524. Investigation of infectious, toxicologic, and immunologic factors associated with NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  525. Investigation of infectious, toxicologic, and immunologic factors associated with NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  526. Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment

    Time frame: At baseline

    This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  527. Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment

    Time frame: At 5 years

    This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  528. Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment

    Time frame: At 10 years

    This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  529. Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment

    Time frame: At 15 years

    This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  530. Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment

    Time frame: At 20 years

    This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  531. Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment

    Time frame: At 25 years

    This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  532. Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment

    Time frame: At 30 years

    This will be assessed either in the presence or in the absence of defined NICMs. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  533. Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs

    Time frame: At baseline

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  534. Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs

    Time frame: At 5 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  535. Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs

    Time frame: At 10 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  536. Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs

    Time frame: At 15 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  537. Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs

    Time frame: At 20 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  538. Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs

    Time frame: At 25 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  539. Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs

    Time frame: At 30 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  540. Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs

    Time frame: At baseline

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  541. Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs

    Time frame: At 5 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  542. Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs

    Time frame: At 10 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  543. Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs

    Time frame: At 15 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  544. Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs

    Time frame: At 20 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  545. Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs

    Time frame: At 25 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  546. Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs

    Time frame: At 30 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  547. Diagnostic value of extracardiac diagnostic techniques in NICMs

    Time frame: At baseline

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  548. Diagnostic value of extracardiac diagnostic techniques in NICMs

    Time frame: At 5 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  549. Diagnostic value of extracardiac diagnostic techniques in NICMs

    Time frame: At 10 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  550. Diagnostic value of extracardiac diagnostic techniques in NICMs

    Time frame: At 15 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  551. Diagnostic value of extracardiac diagnostic techniques in NICMs

    Time frame: At 20 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  552. Diagnostic value of extracardiac diagnostic techniques in NICMs

    Time frame: At 25 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  553. Diagnostic value of extracardiac diagnostic techniques in NICMs

    Time frame: At 30 years

    NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatological/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  554. Occurrence of minor events in DCM

    Time frame: At 1 year

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  555. Occurrence of minor events in DCM

    Time frame: At 3 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  556. Occurrence of minor events in DCM

    Time frame: At 5 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  557. Occurrence of minor events in DCM

    Time frame: At 10 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  558. Occurrence of minor events in DCM

    Time frame: At 15 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  559. Occurrence of minor events in DCM

    Time frame: At 20 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  560. Occurrence of minor events in DCM

    Time frame: At 25 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  561. Occurrence of minor events in DCM

    Time frame: At 30 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  562. Occurrence of minor events in HCM

    Time frame: At 1 year

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  563. Occurrence of minor events in HCM

    Time frame: At 3 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  564. Occurrence of minor events in HCM

    Time frame: At 5 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  565. Occurrence of minor events in HCM

    Time frame: At 10 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  566. Occurrence of minor events in HCM

    Time frame: At 15 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  567. Occurrence of minor events in HCM

    Time frame: At 20 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  568. Occurrence of minor events in HCM

    Time frame: At 25 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  569. Occurrence of minor events in HCM

    Time frame: At 30 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  570. Occurrence of minor events in RCM

    Time frame: At 1 year

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  571. Occurrence of minor events in RCM

    Time frame: At 3 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  572. Occurrence of minor events in RCM

    Time frame: At 5 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  573. Occurrence of minor events in RCM

    Time frame: At 10 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  574. Occurrence of minor events in RCM

    Time frame: At 15 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  575. Occurrence of minor events in RCM

    Time frame: At 20 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  576. Occurrence in minor events in RCM

    Time frame: At 25 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  577. Occurrence of minor events in RCM

    Time frame: At 30 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  578. Occurrence of minor events in ACM

    Time frame: At 1 year

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  579. Occurrence of minor events in ACM

    Time frame: At 3 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  580. Occurrence of minor events in ACM

    Time frame: At 5 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  581. Occurrence of minor events in ACM

    Time frame: At 10 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  582. Occurrence of minor events in ACM

    Time frame: At 15 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  583. Occurrence of minor events in ACM

    Time frame: At 20 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  584. Occurrence of minor events in ACM

    Time frame: At 25 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  585. Occurrence of minor events in ACM

    Time frame: At 30 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  586. Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases

    Time frame: At 1 year

    left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.

    Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  587. Occurrence of minor events in distinct cardiomyopathic phenotypes have been described in some diseases

    Time frame: At 5 years

    left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.

    Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  588. Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases

    Time frame: At 10 years

    left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.

    Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  589. Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases

    Time frame: At 30 years

    left ventricular noncompaction (LVNC), arrhythmogenic mitral valve prolapse (AMVP), peripartum cardiomyopathy (PPCM), Anderson-Fabry disease (AFD), storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases.

    Minor events include non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  590. Occurrence of minor events in overlapping and undefined phenotypes

    Time frame: At 1 year

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  591. Occurrence of minor events in overlapping and undefined phenotypes

    Time frame: At 5 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  592. Occurrence of minor events in overlapping and undefined phenotypes

    Time frame: At 10 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  593. Occurrence of minor events in overlapping and undefined phenotypes

    Time frame: At 30 years

    non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  594. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 1 year

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  595. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 3 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  596. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  597. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  598. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  599. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  600. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  601. Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  602. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 1 year

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  603. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 3 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  604. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  605. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  606. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  607. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  608. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  609. Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  610. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 1 year

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  611. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 3 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  612. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  613. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  614. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  615. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  616. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  617. Identification of biomarkers associated with treatment response for NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  618. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 1 year

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  619. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 3 years

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  620. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 5 years

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  621. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 10 years

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  622. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 15 years

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  623. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 20 years

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  624. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 25 years

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  625. Identification of cost-effective multimodal and multiparametric risk scores for NICMs

    Time frame: At 30 years

    These risk scores will be aimed but not limit to obtain the maximal capability of discriminating heterogeneous outcomes by means of the minimal number of predictors and/or the minimal number of exams and/or the chepest/safest exams.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  626. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 1 year

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  627. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 3 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  628. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  629. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  630. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  631. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  632. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  633. Assessment of the prognostic value of arrhythmias in NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  634. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 1 year

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  635. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 3 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  636. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 5 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  637. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 10 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  638. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 15 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  639. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 20 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  640. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 25 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  641. Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs

    Time frame: At 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  642. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 1 year

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  643. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 3 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  644. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 5 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  645. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 10 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  646. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 15 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  647. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 20 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  648. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 25 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  649. Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events

    Time frame: At 30 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  650. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 1 year

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  651. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 3 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  652. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 5 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  653. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 10 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  654. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 15 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  655. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 20 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  656. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 25 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  657. Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events

    Time frame: At 30 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  658. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 1 year

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  659. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 3 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  660. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 5 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  661. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 10 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  662. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 15 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  663. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 20 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  664. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 25 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  665. Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events

    Time frame: At 30 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  666. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 1 year

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  667. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 3 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  668. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 5 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  669. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 10 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  670. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 15 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  671. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 20 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  672. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 25 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  673. Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events

    Time frame: At 30 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  674. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 1 year

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  675. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 3 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  676. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 5 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  677. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 10 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  678. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 15 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  679. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 20 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  680. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 25 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  681. Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events

    Time frame: At 30 years

    Major events include all-cause death, cardiac death, extra-cardiac disease related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  682. Assessment of epidemiology signatures in DCM

    Time frame: At baseline

  683. Assessment of epidemiology signatures in DCM

    Time frame: At 5 years

  684. Assessment of epidemiology signatures in DCM

    Time frame: At 10 years

  685. Assessment of epidemiology signatures in DCM

    Time frame: At 15 years

  686. Assessment of epidemiology signatures in DCM

    Time frame: At 20 years

  687. Assessment of epidemiology signatures in DCM

    Time frame: At 25 years

  688. Assessment of epidemiology signatures in DCM

    Time frame: At 30 years

  689. Assessment of epidemiology signatures in HCM

    Time frame: At baseline

  690. Assessment of epidemiology signatures in HCM

    Time frame: At 5 years

  691. Assessment of epidemiology signatures in HCM

    Time frame: At 10 years

  692. Assessment of epidemiology signatures in HCM

    Time frame: At 15 years

  693. Assessment of epidemiology signatures in HCM

    Time frame: At 20 years

  694. Assessment of epidemiology signatures in HCM

    Time frame: At 25 years

  695. Assessment of epidemiology signatures in HCM

    Time frame: At 30 years

  696. Assessment of epidemiology signatures in RCM

    Time frame: At baseline

  697. Assessment of epidemiology signatures in RCM

    Time frame: At 5 years

  698. Assessment of epidemiology signatures in RCM

    Time frame: At 10 years

  699. Assessment of epidemiology signatures in RCM

    Time frame: At 15 years

  700. Assessment of epidemiology signatures in RCM

    Time frame: At 20 years

  701. Assessment of epidemiology signatures in RCM

    Time frame: At 25 years

  702. Assessment of epidemiology signatures in RCM

    Time frame: At 30 years

  703. Assessment of epidemiology signatures in ACM

    Time frame: At baseline

  704. Assessment of epidemiology signatures in ACM

    Time frame: At 5 years

  705. Assessment of epidemiology signatures in ACM

    Time frame: At 10 years

  706. Assessment of epidemiology signatures in ACM

    Time frame: At 15 years

  707. Assessment of epidemiology signatures in ACM

    Time frame: At 20 years

  708. Assessment of epidemiology signatures in ACM

    Time frame: At 25 years

  709. Assessment of epidemiology signatures in ACM

    Time frame: At 30 years

  710. Assessment of epidemiology signatures in LVNC

    Time frame: At baseline

  711. Assessment of epidemiology signatures in LVNC

    Time frame: At 5 years

  712. Assessment of epidemiology signatures in LVNC

    Time frame: At 10 years

  713. Assessment of epidemiology signatures in LVNC

    Time frame: At 15 years

  714. Assessment of epidemiology signatures in LVNC

    Time frame: At 20 years

  715. Assessment of epidemiology signatures in LVNC

    Time frame: At 25 years

  716. Assessment of epidemiology signatures in LVNC

    Time frame: At 30 years

  717. Assessment of epidemiology signatures in AMVP

    Time frame: At baseline

  718. Assessment of epidemiology signatures in AMVP

    Time frame: At 5 years

  719. Assessment of epidemiology signatures in AMVP

    Time frame: At 10 years

  720. Assessment of epidemiology signatures in AMVP

    Time frame: At 15 years

  721. Assessment of epidemiology signatures in AMVP

    Time frame: At 20 years

  722. Assessment of epidemiology signatures in AMVP

    Time frame: At 25 years

  723. Assessment of epidemiology signatures in AMVP

    Time frame: At 30 years

  724. Assessment of epidemiology signatures in PPCM

    Time frame: At baseline

  725. Assessment of epidemiology signatures in PPCM

    Time frame: At 5 years

  726. Assessment of epidemiology signatures in PPCM

    Time frame: At 10 years

  727. Assessment of epidemiology signatures in PPCM

    Time frame: At 15 years

  728. Assessment of epidemiology signatures in PPCM

    Time frame: At 20 years

  729. Assessment of epidemiology signatures in PPCM

    Time frame: At 25 years

  730. Assessment of epidemiology signatures in PPCM

    Time frame: At 30 years

  731. Assessment of epidemiology signatures in AFD

    Time frame: At baseline

  732. Assessment of epidemiology signatures in AFD

    Time frame: At 5 years

  733. Assessment of epidemiology signatures in AFD

    Time frame: At 10 years

  734. Assessment of epidemiology signatures in AFD

    Time frame: At 15 years

  735. Assessment of epidemiology signatures in AFD

    Time frame: At 20 years

  736. Assessment of epidemiology signatures in AFD

    Time frame: At 25 years

  737. Assessment of epidemiology signatures in AFD

    Time frame: At 30 years

  738. Assessment of epidemiology signatures in storage and dysmetabolic diseases

    Time frame: At baseline

  739. Assessment of epidemiology signatures in storage and dysmetabolic diseases

    Time frame: At 5 years

  740. Assessment of epidemiology signatures in storage and dysmetabolic diseases

    Time frame: At 10 years

  741. Assessment of epidemiology signatures in storage and dysmetabolic diseases

    Time frame: At 15 years

  742. Assessment of epidemiology signatures in storage and dysmetabolic diseases

    Time frame: At 20 years

  743. Assessment of epidemiology signatures in storage and dysmetabolic diseases

    Time frame: At 25 years

  744. Assessment of epidemiology signatures in storage and dysmetabolic diseases

    Time frame: At 30 years

  745. Assessment of epidemiology signatures in mitochondrial diseases

    Time frame: At baseline

  746. Assessment of epidemiology signatures in mitochondrial diseases

    Time frame: At 5 years

  747. Assessment of epidemiology signatures in mitochondrial diseases

    Time frame: At 10 years

  748. Assessment of epidemiology signatures in mitochondrial diseases

    Time frame: At 15 years

  749. Assessment of epidemiology signatures in mitochondrial diseases

    Time frame: At 20 years

  750. Assessment of epidemiology signatures in mitochondrial diseases

    Time frame: At 25 years

  751. Assessment of epidemiology signatures in mitochondrial diseases

    Time frame: At 30 years

  752. Assessment of epidemiology signatures in channelopathies with structural changes

    Time frame: At baseline

  753. Assessment of epidemiology signatures in channelopathies with structural changes

    Time frame: At 5 years

  754. Assessment of epidemiology signatures in channelopathies with structural changes

    Time frame: At 10 years

  755. Assessment of epidemiology signatures in channelopathies with structural changes

    Time frame: At 15 years

  756. Assessment of epidemiology signatures in channelopathies with structural changes

    Time frame: At 20 years

  757. Assessment of epidemiology signatures in channelopathies with structural changes

    Time frame: At 25 years

  758. Assessment of epidemiology signatures in channelopathies with structural changes

    Time frame: At 30 years

  759. Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  760. Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  761. Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  762. Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  763. Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  764. Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  765. Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  766. Assessment of epidemiology signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  767. Assessment of epidemiology signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  768. Assessment of epidemiology signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  769. Assessment of epidemiology signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  770. Assessment of epidemiology signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  771. Assessment of epidemiology signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  772. Assessment of epidemiology signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  773. Assessment of etiology signatures in DCM

    Time frame: At baseline

  774. Assessment of etiology signatures in DCM

    Time frame: At 5 years

  775. Assessment of etiology signatures in DCM

    Time frame: At 10 years

  776. Assessment of etiology signatures in DCM

    Time frame: At 15 years

  777. Assessment of etiology signatures in DCM

    Time frame: At 20 years

  778. Assessment of etiology signatures in DCM

    Time frame: At 25 years

  779. Assessment of etiology signatures in DCM

    Time frame: At 30 years

  780. Assessment of etiology signatures in HCM

    Time frame: At baseline

  781. Assessment of etiology signatures in HCM

    Time frame: At 5 years

  782. Assessment of etiology signatures in HCM

    Time frame: At 10 years

  783. Assessment of etiology signatures in HCM

    Time frame: At 15 years

  784. Assessment of etiology signatures in HCM

    Time frame: At 20 years

  785. Assessment of etiology signatures in HCM

    Time frame: At 25 years

  786. Assessment of etiology signatures in HCM

    Time frame: At 30 years

  787. Assessment of etiology signatures in RCM

    Time frame: At baseline

  788. Assessment of etiology signatures in RCM

    Time frame: At 5 years

  789. Assessment of etiology signatures in RCM

    Time frame: At 10 years

  790. Assessment of etiology signatures in RCM

    Time frame: At 15 years

  791. Assessment of etiology signatures in RCM

    Time frame: At 20 years

  792. Assessment of etiology signatures in RCM

    Time frame: At 25 years

  793. Assessment of etiology signatures in RCM

    Time frame: At 30 years

  794. Assessment of etiology signatures in ACM

    Time frame: At baseline

  795. Assessment of etiology signatures in ACM

    Time frame: At 5 years

  796. Assessment of etiology signatures in ACM

    Time frame: At 10 years

  797. Assessment of etiology signatures in ACM

    Time frame: At 15 years

  798. Assessment of etiology signatures in ACM

    Time frame: At 20 years

  799. Assessment of etiology signatures in ACM

    Time frame: At 25 years

  800. Assessment of etiology signatures in ACM

    Time frame: At 30 years

  801. Assessment of etiology signatures in LVNC

    Time frame: At baseline

  802. Assessment of etiology signatures in LVNC

    Time frame: At 5 years

  803. Assessment of etiology signatures in LVNC

    Time frame: At 10 years

  804. Assessment of etiology signatures in LVNC

    Time frame: At 15 years

  805. Assessment of etiology signatures in LVNC

    Time frame: At 20 years

  806. Assessment of etiology signatures in LVNC

    Time frame: At 25 years

  807. Assessment of etiology signatures in LVNC

    Time frame: At 30 years

  808. Assessment of etiology signatures in AMVP

    Time frame: At baseline

  809. Assessment of etiology signatures in AMVP

    Time frame: At 5 years

  810. Assessment of etiology signatures in AMVP

    Time frame: At 10 years

  811. Assessment of etiology signatures in AMVP

    Time frame: At 15 years

  812. Assessment of etiology signatures in AMVP

    Time frame: At 20 years

  813. Assessment of etiology signatures in AMVP

    Time frame: At 25 years

  814. Assessment of etiology signatures in AMVP

    Time frame: At 30 years

  815. Assessment of etiology signatures in PPCM

    Time frame: At baseline

  816. Assessment of etiology signatures in PPCM

    Time frame: At 5 years

  817. Assessment of etiology signatures in PPCM

    Time frame: At 10 years

  818. Assessment of etiology signatures in PPCM

    Time frame: At 15 years

  819. Assessment of etiology signatures in PPCM

    Time frame: At 20 years

  820. Assessment of etiology signatures in PPCM

    Time frame: At 25 years

  821. Assessment of etiology signatures in PPCM

    Time frame: At 30 years

  822. Assessment of etiology signatures in AFD

    Time frame: At baseline

  823. Assessment of etiology signatures in AFD

    Time frame: At 5 years

  824. Assessment of etiology signatures in AFD

    Time frame: At 10 years

  825. Assessment of etiology signatures in AFD

    Time frame: At 15 years

  826. Assessment of etiology signatures in AFD

    Time frame: At 20 years

  827. Assessment of etiology signatures in AFD

    Time frame: At 25 years

  828. Assessment of etiology signatures in AFD

    Time frame: At 30 years

  829. Assessment of etiology signatures in storage and dysmetabolic diseases

    Time frame: At baseline

  830. Assessment of etiology signatures in storage and dysmetabolic diseases

    Time frame: At 5 years

  831. Assessment of etiology signatures in storage and dysmetabolic diseases

    Time frame: At 10 years

  832. Assessment of etiology signatures in storage and dysmetabolic diseases

    Time frame: At 15 years

  833. Assessment of etiology signatures in storage and dysmetabolic diseases

    Time frame: At 20 years

  834. Assessment of etiology signatures in storage and dysmetabolic diseases

    Time frame: At 25 years

  835. Assessment of etiology signatures in storage and dysmetabolic diseases

    Time frame: At 30 years

  836. Assessment of etiology signatures in mitochondrial diseases

    Time frame: At baseline

  837. Assessment of etiology signatures in mitochondrial diseases

    Time frame: At 5 years

  838. Assessment of etiology signatures in mitochondrial diseases

    Time frame: At 10 years

  839. Assessment of etiology signatures in mitochondrial diseases

    Time frame: At 15 years

  840. Assessment of etiology signatures in mitochondrial diseases

    Time frame: At 20 years

  841. Assessment of etiology signatures in mitochondrial diseases

    Time frame: At 25 years

  842. Assessment of etiology signatures in mitochondrial diseases

    Time frame: At 30 years

  843. Assessment of etiology signatures in channelopathies with structural changes

    Time frame: At baseline

  844. Assessment of etiology signatures in channelopathies with structural changes

    Time frame: At 5 years

  845. Assessment of etiology signatures in channelopathies with structural changes

    Time frame: At 10 years

  846. Assessment of etiology signatures in channelopathies with structural changes

    Time frame: At 15 years

  847. Assessment of etiology signatures in channelopathies with structural changes

    Time frame: At 20 years

  848. Assessment of etiology signatures in channelopathies with structural changes

    Time frame: At 25 years

  849. Assessment of etiology signatures in channelopathies with structural changes

    Time frame: At 30 years

  850. Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  851. Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  852. Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  853. Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  854. Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  855. Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  856. Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  857. Assessment of etiology signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  858. Assessment of etiology signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  859. Assessment of etiology signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  860. Assessment of etiology signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  861. Assessment of etiology signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  862. Assessment of etiology signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  863. Assessment of pathophysiology signatures in DCM

    Time frame: At baseline

  864. Assessment of pathophysiology signatures in DCM

    Time frame: At 5 years

  865. Assessment of pathophysiology signatures in DCM

    Time frame: At 10 years

  866. Assessment of pathophysiology signatures in DCM

    Time frame: At 15 years

  867. Assessment of pathophysiology signatures in DCM

    Time frame: At 20 years

  868. Assessment of pathophysiology signatures in DCM

    Time frame: At 25 years

  869. Assessment of pathophysiology signatures in DCM

    Time frame: At 30 years

  870. Assessment of pathophysiology signatures in HCM

    Time frame: At baseline

  871. Assessment of pathophysiology signatures in HCM

    Time frame: At 5 years

  872. Assessment of pathophysiology signatures in HCM

    Time frame: At 10 years

  873. Assessment of pathophysiology signatures in HCM

    Time frame: At 15 years

  874. Assessment of pathophysiology signatures in HCM

    Time frame: At 20 years

  875. Assessment of pathophysiology signatures in HCM

    Time frame: At 25 years

  876. Assessment of pathophysiology signatures in HCM

    Time frame: At 30 years

  877. Assessment of pathophysiology signatures in RCM

    Time frame: At baseline

  878. Assessment of pathophysiology signatures in RCM

    Time frame: At 5 years

  879. Assessment of pathophysiology signatures in RCM

    Time frame: At 10 years

  880. Assessment of pathophysiology signatures in RCM

    Time frame: At 15 years

  881. Assessment of pathophysiology signatures in RCM

    Time frame: At 20 years

  882. Assessment of pathophysiology signatures in RCM

    Time frame: At 25 years

  883. Assessment of pathophysiology signatures in RCM

    Time frame: At 30 years

  884. Assessment of pathophysiology signatures in ACM

    Time frame: At baseline

  885. Assessment of pathophysiology signatures in ACM

    Time frame: At 5 years

  886. Assessment of pathophysiology signatures in ACM

    Time frame: At 10 years

  887. Assessment of pathophysiology signatures in ACM

    Time frame: At 15 years

  888. Assessment of pathophysiology signatures in ACM

    Time frame: At 20 years

  889. Assessment of pathophysiology signatures in ACM

    Time frame: At 25 years

  890. Assessment of pathophysiology signatures in ACM

    Time frame: At 30 years

  891. Assessment of pathophysiology signatures in LVNC

    Time frame: At baseline

  892. Assessment of pathophysiology signatures in LVNC

    Time frame: At 5 years

  893. Assessment of pathophysiology signatures in LVNC

    Time frame: At 10 years

  894. Assessment of pathophysiology signatures in LVNC

    Time frame: At 15 years

  895. Assessment of pathophysiology signatures in LVNC

    Time frame: At 20 years

  896. Assessment of pathophysiology signatures in LVNC

    Time frame: At 25 years

  897. Assessment of pathophysiology signatures in LVNC

    Time frame: At 30 years

  898. Assessment of pathophysiology signatures in AMVP

    Time frame: At baseline

  899. Assessment of pathophysiology signatures in AMVP

    Time frame: At 5 years

  900. Assessment of pathophysiology signatures in AMVP

    Time frame: At 10 years

  901. Assessment of pathophysiology signatures in AMVP

    Time frame: At 15 years

  902. Assessment of pathophysiology signatures in AMVP

    Time frame: At 20 years

  903. Assessment of pathophysiology signatures in AMVP

    Time frame: At 25 years

  904. Assessment of pathophysiology signatures in AMVP

    Time frame: At 30 years

  905. Assessment of pathophysiology signatures in PPCM

    Time frame: At baseline

  906. Assessment of pathophysiology signatures in PPCM

    Time frame: At 5 years

  907. Assessment of pathophysiology signatures in PPCM

    Time frame: At 10 years

  908. Assessment of pathophysiology signatures in PPCM

    Time frame: At 15 years

  909. Assessment of pathophysiology signatures in PPCM

    Time frame: At 20 years

  910. Assessment of pathophysiology signatures in PPCM

    Time frame: At 25 years

  911. Assessment of pathophysiology signatures in PPCM

    Time frame: At 30 years

  912. Assessment of pathophysiology signatures in AFD

    Time frame: At baseline

  913. Assessment of pathophysiology signatures in AFD

    Time frame: At 5 years

  914. Assessment of pathophysiology signatures in AFD

    Time frame: At 10 years

  915. Assessment of pathophysiology signatures in AFD

    Time frame: At 15 years

  916. Assessment of pathophysiology signatures in AFD

    Time frame: At 20 years

  917. Assessment of pathophysiology signatures in AFD

    Time frame: At 25 years

  918. Assessment of pathophysiology signatures in AFD

    Time frame: At 30 years

  919. Assessment of pathophysiology signatures in storage and dysmetabolic diseases

    Time frame: At baseline

  920. Assessment of pathophysiology signatures in storage and dysmetabolic diseases

    Time frame: At 5 years

  921. Assessment of pathophysiology signatures in storage and dysmetabolic diseases

    Time frame: At 10 years

  922. Assessment of pathophysiology signatures in storage and dysmetabolic diseases

    Time frame: At 15 years

  923. Assessment of pathophysiology signatures in storage and dysmetabolic diseases

    Time frame: At 20 years

  924. Assessment of pathophysiology signatures in storage and dysmetabolic diseases

    Time frame: At 25 years

  925. Assessment of pathophysiology signatures in storage and dysmetabolic diseases

    Time frame: At 30 years

  926. Assessment of pathophysiology signatures in mitochondrial diseases

    Time frame: At baseline

  927. Assessment of pathophysiology signatures in mitochondrial diseases

    Time frame: At 5 years

  928. Assessment of pathophysiology signatures in mitochondrial diseases

    Time frame: At 10 years

  929. Assessment of pathophysiology signatures in mitochondrial diseases

    Time frame: At 15 years

  930. Assessment of pathophysiology signatures in mitochondrial diseases

    Time frame: At 20 years

  931. Assessment of pathophysiology signatures in mitochondrial diseases

    Time frame: At 25 years

  932. Assessment of pathophysiology signatures in mitochondrial diseases

    Time frame: At 30 years

  933. Assessment of pathophysiology signatures in channelopathies with structural changes

    Time frame: At baseline

  934. Assessment of pathophysiology signatures in channelopathies with structural changes

    Time frame: At 5 years

  935. Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  936. Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  937. Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  938. Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  939. Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  940. Assessment of pathophysiology signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  941. Assessment of pathophysiology signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  942. Assessment of pathophysiology signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  943. Assessment of pathophysiology signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  944. Assessment of pathophysiology signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  945. Assessment of pathophysiology signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  946. Assessment of pathophysiology signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  947. Assessment of genotype-phenotype signatures in DCM

    Time frame: At baseline

  948. Assessment of genotype-phenotype signatures in DCM

    Time frame: At 5 years

  949. Assessment of genotype-phenotype signatures in DCM

    Time frame: At 10 years

  950. Assessment of genotype-phenotype signatures in DCM

    Time frame: At 15 years

  951. Assessment of genotype-phenotype signatures in DCM

    Time frame: At 20 years

  952. Assessment of genotype-phenotype signatures in DCM

    Time frame: At 25 years

  953. Assessment of genotype-phenotype signatures in DCM

    Time frame: At 30 years

  954. Assessment of genotype-phenotype signatures in HCM

    Time frame: At baseline

  955. Assessment of genotype-phenotype signatures in HCM

    Time frame: At 5 years

  956. Assessment of genotype-phenotype signatures in HCM

    Time frame: At 10 years

  957. Assessment of genotype-phenotype signatures in HCM

    Time frame: At 15 years

  958. Assessment of genotype-phenotype signatures in HCM

    Time frame: At 20 years

  959. Assessment of genotype-phenotype signatures in HCM

    Time frame: At 25 years

  960. Assessment of genotype-phenotype signatures in HCM

    Time frame: At 30 years

  961. Assessment of genotype-phenotype signatures in RCM

    Time frame: At baseline

  962. Assessment of genotype-phenotype signatures in RCM

    Time frame: At 5 years

  963. Assessment of genotype-phenotype signatures in RCM

    Time frame: At 10 years

  964. Assessment of genotype-phenotype signatures in RCM

    Time frame: At 15 years

  965. Assessment of genotype-phenotype signatures in RCM

    Time frame: At 20 years

  966. Assessment of genotype-phenotype signatures in RCM

    Time frame: At 25 years

  967. Assessment of genotype-phenotype signatures in RCM

    Time frame: At 30 years

  968. Assessment of genotype-phenotype signatures in ACM

    Time frame: At baseline

  969. Assessment of genotype-phenotype signatures in ACM

    Time frame: At 5 years

  970. Assessment of genotype-phenotype signatures in ACM

    Time frame: At 10 years

  971. Assessment of genotype-phenotype signatures in ACM

    Time frame: At 15 years

  972. Assessment of genotype-phenotype signatures in ACM

    Time frame: At 20 years

  973. Assessment of genotype-phenotype signatures in ACM

    Time frame: At 25 years

  974. Assessment of genotype-phenotype signatures in ACM

    Time frame: At 30 years

  975. Assessment of genotype-phenotype signatures in LVNC

    Time frame: At baseline

  976. Assessment of genotype-phenotype signatures in LVNC

    Time frame: At 5 years

  977. Assessment of genotype-phenotype signatures in LVNC

    Time frame: At 10 years

  978. Assessment of genotype-phenotype signatures in LVNC

    Time frame: At 15 years

  979. Assessment of genotype-phenotype signatures in LVNC

    Time frame: At 20 years

  980. Assessment of genotype-phenotype signatures in LVNC

    Time frame: At 25 years

  981. Assessment of genotype-phenotype signatures in LVNC

    Time frame: At 30 years

  982. Assessment of genotype-phenotype signatures in AMVP

    Time frame: At baseline

  983. Assessment of genotype-phenotype signatures in AMVP

    Time frame: At 5 years

  984. Assessment of genotype-phenotype signatures in AMVP

    Time frame: At 10 years

  985. Assessment of genotype-phenotype signatures in AMVP

    Time frame: At 15 years

  986. Assessment of genotype-phenotype signatures in AMVP

    Time frame: At 20 years

  987. Assessment of genotype-phenotype signatures in AMVP

    Time frame: At 25 years

  988. Assessment of genotype-phenotype signatures in AMVP

    Time frame: At 30 years

  989. Assessment of genotype-phenotype signatures in PPCM

    Time frame: At baseline

  990. Assessment of genotype-phenotype signatures in PPCM

    Time frame: At 5 years

  991. Assessment of genotype-phenotype signatures in PPCM

    Time frame: At 10 years

  992. Assessment of genotype-phenotype signatures in PPCM

    Time frame: At 15 years

  993. Assessment of genotype-phenotype signatures in PPCM

    Time frame: At 20 years

  994. Assessment of genotype-phenotype signatures in PPCM

    Time frame: At 25 years

  995. Assessment of genotype-phenotype signatures in PPCM

    Time frame: At 30 years

  996. Assessment of genotype-phenotype signatures in AFD

    Time frame: At baseline

  997. Assessment of genotype-phenotype signatures in AFD

    Time frame: At 5 years

  998. Assessment of genotype-phenotype signatures in AFD

    Time frame: At 10 years

  999. Assessment of genotype-phenotype signatures in AFD

    Time frame: At 15 years

  1000. Assessment of genotype-phenotype signatures in AFD

    Time frame: At 20 years

  1001. Assessment of genotype-phenotype signatures in AFD

    Time frame: At 25 years

  1002. Assessment of genotype-phenotype signatures in AFD

    Time frame: At 30 years

  1003. Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases

    Time frame: At baseline

  1004. Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases

    Time frame: At 5 years

  1005. Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases

    Time frame: At 10 years

  1006. Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases

    Time frame: At 15 years

  1007. Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases

    Time frame: At 20 years

  1008. Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases

    Time frame: At 25 years

  1009. Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases

    Time frame: At 30 years

  1010. Assessment of genotype-phenotype signatures in mitochondrial diseases

    Time frame: At baseline

  1011. Assessment of genotype-phenotype signatures in mitochondrial diseases

    Time frame: At 5 years

  1012. Assessment of genotype-phenotype signatures in mitochondrial diseases

    Time frame: At 10 years

  1013. Assessment of genotype-phenotype signatures in mitochondrial diseases

    Time frame: At 15 years

  1014. Assessment of genotype-phenotype signatures in mitochondrial diseases

    Time frame: At 20 years

  1015. Assessment of genotype-phenotype signatures in mitochondrial diseases

    Time frame: At 25 years

  1016. Assessment of genotype-phenotype signatures in mitochondrial diseases

    Time frame: At 30 years

  1017. Assessment of genotype-phenotype signatures in channelopathies with structural changes

    Time frame: At baseline

  1018. Assessment of genotype-phenotype signatures in channelopathies with structural changes

    Time frame: At 5 years

  1019. Assessment of genotype-phenotype signatures in channelopathies with structural changes

    Time frame: At 10 years

  1020. Assessment of genotype-phenotype signatures in channelopathies with structural changes

    Time frame: At 15 years

  1021. Assessment of genotype-phenotype signatures in channelopathies with structural changes

    Time frame: At 20 years

  1022. Assessment of genotype-phenotype signatures in channelopathies with structural changes

    Time frame: At 25 years

  1023. Assessment of genotype-phenotype signatures in channelopathies with structural changes

    Time frame: At 30 years

  1024. Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1025. Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1026. Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1027. Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1028. Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1029. Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1030. Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1031. Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  1032. Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  1033. Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  1034. Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  1035. Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  1036. Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  1037. Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  1038. Assessment of arrhythmia signatures in DCM

    Time frame: At baseline

  1039. Assessment of arrhythmia signatures in DCM

    Time frame: At 5 years

  1040. Assessment of arrhythmia signatures in DCM

    Time frame: At 10 years

  1041. Assessment of arrhythmia signatures in DCM

    Time frame: At 15 years

  1042. Assessment of arrhythmia signatures in DCM

    Time frame: At 20 years

  1043. Assessment of arrhythmia signatures in DCM

    Time frame: At 25 years

  1044. Assessment of arrhythmia signatures in DCM

    Time frame: At 30 years

  1045. Assessment of arrhythmia signatures in HCM

    Time frame: At baseline

  1046. Assessment of arrhythmia signatures in HCM

    Time frame: At 5 years

  1047. Assessment of arrhythmia signatures in RCM

    Time frame: Every 10 years

  1048. Assessment of arrhythmia signatures in ACM

    Time frame: Every 15 years

  1049. Assessment of arrhythmia signatures in ACM

    Time frame: Every 20 years

  1050. Assessment of arrhythmia signatures in ACM

    Time frame: Every 25 years

  1051. Assessment of arrhythmia signatures in ACM

    Time frame: Every 30 years

  1052. Assessment of arrhythmia signatures in LVNC

    Time frame: At baseline

  1053. Assessment of arrhythmia signatures in LVNC

    Time frame: At 5 years

  1054. Assessment of arrhythmia signatures in LVNC

    Time frame: At 10 years

  1055. Assessment of arrhythmia signatures in LVNC

    Time frame: At 15 years

  1056. Assessment of arrhythmia signatures in LVNC

    Time frame: At 20 years

  1057. Assessment of arrhythmia signatures in LVNC

    Time frame: At 25 years

  1058. Assessment of arrhythmia signatures in LVNC

    Time frame: At 30 years

  1059. Assessment of arrhythmia signatures in AMVP

    Time frame: At baseline

  1060. Assessment of arrhythmia signatures in AMVP

    Time frame: At 5 years

  1061. Assessment of arrhythmia signatures in AMVP

    Time frame: At 10 years

  1062. Assessment of arrhythmia signatures in AMVP

    Time frame: At 15 years

  1063. Assessment of arrhythmia signatures in AMVP

    Time frame: At 20 years

  1064. Assessment of arrhythmia signatures in AMVP

    Time frame: At 25 years

  1065. Assessment of arrhythmia signatures in AMVP

    Time frame: At 30 years

  1066. Assessment of arrhythmia signatures in PPCM

    Time frame: At baseline

  1067. Assessment of arrhythmia signatures in PPCM

    Time frame: At 5 years

  1068. Assessment of arrhythmia signatures in PPCM

    Time frame: At 10 years

  1069. Assessment of arrhythmia signatures in PPCM

    Time frame: At 15 years

  1070. Assessment of arrhythmia signatures in PPCM

    Time frame: At 20 years

  1071. Assessment of arrhythmia signatures in PPCM

    Time frame: At 25 years

  1072. Assessment of arrhythmia signatures in PPCM

    Time frame: At 30 years

  1073. Assessment of arrhythmia signatures in AFD

    Time frame: At baseline

  1074. Assessment of arrhythmia signatures in AFD

    Time frame: At 5 years

  1075. Assessment of arrhythmia signatures in AFD

    Time frame: At 10 years

  1076. Assessment of arrhythmia signatures in AFD

    Time frame: At 15 years

  1077. Assessment of arrhythmia signatures in AFD

    Time frame: At 20 years

  1078. Assessment of arrhythmia signatures in AFD

    Time frame: At 25 years

  1079. Assessment of arrhythmia signatures in AFD

    Time frame: At 30 years

  1080. Assessment of arrhythmia signatures in storage and dysmetabolic diseases

    Time frame: At baseline

  1081. Assessment of arrhythmia signatures in storage and dysmetabolic diseases

    Time frame: At 5 years

  1082. Assessment of arrhythmia signatures in storage and dysmetabolic diseases

    Time frame: At 10 years

  1083. Assessment of arrhythmia signatures in storage and dysmetabolic diseases

    Time frame: At 15 years

  1084. Assessment of arrhythmia signatures in storage and dysmetabolic diseases

    Time frame: At 20 years

  1085. Assessment of arrhythmia signatures in storage and dysmetabolic diseases

    Time frame: At 25 years

  1086. Assessment of arrhythmia signatures in storage and dysmetabolic diseases

    Time frame: At 30 years

  1087. Assessment of arrhythmia signatures in mitochondrial diseases

    Time frame: At baseline

  1088. Assessment of arrhythmia signatures in mitochondrial diseases

    Time frame: At 5 years

  1089. Assessment of arrhythmia signatures in mitochondrial diseases

    Time frame: At 10 years

  1090. Assessment of arrhythmia signatures in mitochondrial diseases

    Time frame: At 15 years

  1091. Assessment of arrhythmia signatures in mitochondrial diseases

    Time frame: At 20 years

  1092. Assessment of arrhythmia signatures in mitochondrial diseases

    Time frame: At 25 years

  1093. Assessment of arrhythmia signatures in mitochondrial diseases

    Time frame: At 30 years

  1094. Assessment of arrhythmia signatures in channelopathies with structural changes

    Time frame: At baseline

  1095. Assessment of arrhythmia signatures in channelopathies with structural changes

    Time frame: At 5 years

  1096. Assessment of arrhythmia signatures in channelopathies with structural changes

    Time frame: At 10 years

  1097. Assessment of arrhythmia signatures in channelopathies with structural changes

    Time frame: At 15 years

  1098. Assessment of arrhythmia signatures in channelopathies with structural changes

    Time frame: At 20 years

  1099. Assessment of arrhythmia signatures in channelopathies with structural changes

    Time frame: At 25 years

  1100. Assessment of arrhythmia signatures in channelopathies with structural changes

    Time frame: At 30 years

  1101. Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1102. Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1103. Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1104. Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1105. Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1106. Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1107. Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1108. Assessment of arrhythmia signatures in overlapping and undefined phenotype

    Time frame: At baseline

  1109. Assessment of arrhythmia signatures in overlapping and undefined phenotype

    Time frame: At 5 years

  1110. Assessment of arrhythmia signatures in overlapping and undefined phenotype

    Time frame: At 10 years

  1111. Assessment of arrhythmia signatures in overlapping and undefined phenotype

    Time frame: At 15 years

  1112. Assessment of arrhythmia signatures in overlapping and undefined phenotype

    Time frame: At 20 years

  1113. Assessment of arrhythmia signatures in overlapping and undefined phenotype

    Time frame: At 25 years

  1114. Assessment of arrhythmia signatures in overlapping and undefined phenotype

    Time frame: At 30 years

  1115. Assessment of M-Infl signatures in DCM

    Time frame: At baseline

  1116. Assessment of M-Infl signatures in DCM

    Time frame: At 5 years

  1117. Assessment of M-Infl signatures in DCM

    Time frame: At 10 years

  1118. Assessment of M-Infl signatures in DCM

    Time frame: At 15 years

  1119. Assessment of M-Infl signatures in DCM

    Time frame: At 20 years

  1120. Assessment of M-Infl signatures in DCM

    Time frame: At 25 years

  1121. Assessment of M-Infl signatures in DCM

    Time frame: At 30 years

  1122. Assessment of M-Infl signatures in HCM

    Time frame: At baseline

  1123. Assessment of M-Infl signatures in HCM

    Time frame: At 5 years

  1124. Assessment of M-Infl signatures in HCM

    Time frame: At 10 years

  1125. Assessment of M-Infl signatures in HCM

    Time frame: At 15 years

  1126. Assessment of M-Infl signatures in HCM

    Time frame: At 20 years

  1127. Assessment of M-Infl signatures in HCM

    Time frame: At 25 years

  1128. Assessment of M-Infl signatures in HCM

    Time frame: At 30 years

  1129. Assessment of M-Infl signatures in RCM

    Time frame: At baseline

  1130. Assessment of M-Infl signatures in RCM

    Time frame: At 5 years

  1131. Assessment of M-Infl signatures in RCM

    Time frame: At 10 years

  1132. Assessment of M-Infl signatures in RCM

    Time frame: At 15 years

  1133. Assessment of M-Infl signatures in RCM

    Time frame: At 20 years

  1134. Assessment of M-Infl signatures in RCM

    Time frame: At 25 years

  1135. Assessment of M-Infl signatures in RCM

    Time frame: At 30 years

  1136. Assessment of M-Infl signatures in ACM

    Time frame: At baseline

  1137. Assessment of M-Infl signatures in ACM

    Time frame: At 5 years

  1138. Assessment of M-Infl signatures in ACM

    Time frame: At 10 years

  1139. Assessment of M-Infl signatures in ACM

    Time frame: At 15 years

  1140. Assessment of M-Infl signatures in ACM

    Time frame: At 20 years

  1141. Assessment of M-Infl signatures in ACM

    Time frame: At 25 years

  1142. Assessment of M-Infl signatures in ACM

    Time frame: At 30 years

  1143. Assessment of M-Infl signatures in LVNC

    Time frame: At baseline

  1144. Assessment of M-Infl signatures in LVNC

    Time frame: At 5 years

  1145. Assessment of M-Infl signatures in LVNC

    Time frame: At 10 years

  1146. Assessment of M-Infl signatures in LVNC

    Time frame: At 15 years

  1147. Assessment of M-Infl signatures in LVNC

    Time frame: At 20 years

  1148. Assessment of M-Infl signatures in LVNC

    Time frame: At 25 years

  1149. Assessment of M-Infl signatures in LVNC

    Time frame: At 30 years

  1150. Assessment of M-Infl signatures in AMVP

    Time frame: At baseline

  1151. Assessment of M-Infl signatures in AMVP

    Time frame: At 5 years

  1152. Assessment of M-Infl signatures in AMVP

    Time frame: At 10 years

  1153. Assessment of M-Infl signatures in AMVP

    Time frame: At 15 years

  1154. Assessment of M-Infl signatures in AMVP

    Time frame: At 20 years

  1155. Assessment of M-Infl signatures in AMVP

    Time frame: At 25 years

  1156. Assessment of M-Infl signatures in AMVP

    Time frame: At 30 years

  1157. Assessment of M-Infl signatures in PPCM

    Time frame: At baseline

  1158. Assessment of M-Infl signatures in PPCM

    Time frame: At 5 years

  1159. Assessment of M-Infl signatures in PPCM

    Time frame: At 10 years

  1160. Assessment of M-Infl signatures in PPCM

    Time frame: At 15 years

  1161. Assessment of M-Infl signatures in PPCM

    Time frame: At 20 years

  1162. Assessment of M-Infl signatures in PPCM

    Time frame: At 25 years

  1163. Assessment of M-Infl signatures in PPCM

    Time frame: At 30 years

  1164. Assessment of M-Infl signatures in AFD

    Time frame: At baseline

  1165. Assessment of M-Infl signatures in AFD

    Time frame: At 5 years

  1166. Assessment of M-Infl signatures in AFD

    Time frame: At 10 years

  1167. Assessment of M-Infl signatures in AFD

    Time frame: At 15 years

  1168. Assessment of M-Infl signatures in AFD

    Time frame: At 20 years

  1169. Assessment of M-Infl signatures in AFD

    Time frame: At 25 years

  1170. Assessment of M-Infl signatures in AFD

    Time frame: At 30 years

  1171. Assessment of M-Infl signatures in storage and dysmetabolic diseases

    Time frame: At baseline

  1172. Assessment of M-Infl signatures in storage and dysmetabolic diseases

    Time frame: At 5 years

  1173. Assessment of M-Infl signatures in storage and dysmetabolic diseases

    Time frame: At 10 years

  1174. Assessment of M-Infl signatures in storage and dysmetabolic diseases

    Time frame: At 15 years

  1175. Assessment of M-Infl signatures in storage and dysmetabolic diseases

    Time frame: At 20 years

  1176. Assessment of M-Infl signatures in storage and dysmetabolic diseases

    Time frame: At 25 years

  1177. Assessment of M-Infl signatures in storage and dysmetabolic diseases

    Time frame: At 30 years

  1178. Assessment of M-Infl signatures in mitochondrial diseases

    Time frame: At baseline

  1179. Assessment of M-Infl signatures in mitochondrial diseases

    Time frame: At 5 years

  1180. Assessment of M-Infl signatures in mitochondrial diseases

    Time frame: At 10 years

  1181. Assessment of M-Infl signatures in mitochondrial diseases

    Time frame: At 15 years

  1182. Assessment of M-Infl signatures in mitochondrial diseases

    Time frame: At 20 years

  1183. Assessment of M-Infl signatures in mitochondrial diseases

    Time frame: At 25 years

  1184. Assessment of M-Infl signatures in mitochondrial diseases

    Time frame: At 30 years

  1185. Assessment of M-Infl signatures in channelopathies with structural changes

    Time frame: At baseline

  1186. Assessment of M-Infl signatures in channelopathies with structural changes

    Time frame: At 5 years

  1187. Assessment of M-Infl signatures in channelopathies with structural changes

    Time frame: At 10 years

  1188. Assessment of M-Infl signatures in channelopathies with structural changes

    Time frame: At 15 years

  1189. Assessment of M-Infl signatures in channelopathies with structural changes

    Time frame: At 20 years

  1190. Assessment of M-Infl signatures in channelopathies with structural changes

    Time frame: At 25 years

  1191. Assessment of M-Infl signatures in channelopathies with structural changes

    Time frame: At 30 years

  1192. Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1193. Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1194. Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1195. Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1196. Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1197. Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1198. Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1199. Assessment of M-Infl signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  1200. Assessment of M-Infl signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  1201. Assessment of M-Infl signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  1202. Assessment of M-Infl signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  1203. Assessment of M-Infl signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  1204. Assessment of M-Infl signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  1205. Assessment of M-Infl signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  1206. Assessment of extracardiac signatures in DCM

    Time frame: At baseline

  1207. Assessment of extracardiac signatures in DCM

    Time frame: At 5 years

  1208. Assessment of extracardiac signatures in DCM

    Time frame: At 10 years

  1209. Assessment of extracardiac signatures in DCM

    Time frame: At 15 years

  1210. Assessment of extracardiac signatures in DCM

    Time frame: At 20 years

  1211. Assessment of extracardiac signatures in DCM

    Time frame: At 25 years

  1212. Assessment of extracardiac signatures in DCM

    Time frame: At 30 years

  1213. Assessment of extracardiac signatures in HCM

    Time frame: At baseline

  1214. Assessment of extracardiac signatures in HCM

    Time frame: At 5 years

  1215. Assessment of extracardiac signatures in HCM

    Time frame: At 10 years

  1216. Assessment of extracardiac signatures in HCM

    Time frame: At 15 years

  1217. Assessment of extracardiac signatures in HCM

    Time frame: At 20 years

  1218. Assessment of extracardiac signatures in HCM

    Time frame: At 25 years

  1219. Assessment of extracardiac signatures in HCM

    Time frame: At 30 years

  1220. Assessment of extracardiac signatures in RCM

    Time frame: At baseline

  1221. Assessment of extracardiac signatures in RCM

    Time frame: At 5 years

  1222. Assessment of extracardiac signatures in RCM

    Time frame: At 10 years

  1223. Assessment of extracardiac signatures in RCM

    Time frame: At 15 years

  1224. Assessment of extracardiac signatures in RCM

    Time frame: At 20 years

  1225. Assessment of extracardiac signatures in RCM

    Time frame: At 25 years

  1226. Assessment of extracardiac signatures in RCM

    Time frame: At 30 years

  1227. Assessment of extracardiac signatures in ACM

    Time frame: At baseline

  1228. Assessment of extracardiac signatures in ACM

    Time frame: At 5 years

  1229. Assessment of extracardiac signatures in ACM

    Time frame: At 10 years

  1230. Assessment of extracardiac signatures in ACM

    Time frame: At 15 years

  1231. Assessment of extracardiac signatures in ACM

    Time frame: At 20 years

  1232. Assessment of extracardiac signatures in ACM

    Time frame: At 25 years

  1233. Assessment of extracardiac signatures in ACM

    Time frame: At 30 years

  1234. Assessment of extracardiac signatures in LVNC

    Time frame: At baseline

  1235. Assessment of extracardiac signatures in LVNC

    Time frame: At 5 years

  1236. Assessment of extracardiac signatures in LVNC

    Time frame: At 10 years

  1237. Assessment of extracardiac signatures in LVNC

    Time frame: At 15 years

  1238. Assessment of extracardiac signatures in LVNC

    Time frame: At 20 years

  1239. Assessment of extracardiac signatures in LVNC

    Time frame: At 25 years

  1240. Assessment of extracardiac signatures in LVNC

    Time frame: At 30 years

  1241. Assessment of extracardiac signatures in AMVP

    Time frame: At baseline

  1242. Assessment of extracardiac signatures in AMVP

    Time frame: At 5 years

  1243. Assessment of extracardiac signatures in AMVP

    Time frame: At 10 years

  1244. Assessment of extracardiac signatures in AMVP

    Time frame: At 15 years

  1245. Assessment of extracardiac signatures in AMVP

    Time frame: At 20 years

  1246. Assessment of extracardiac signatures in AMVP

    Time frame: At 25 years

  1247. Assessment of extracardiac signatures in AMVP

    Time frame: At 30 years

  1248. Assessment of extracardiac signatures in PPCM

    Time frame: At baseline

  1249. Assessment of extracardiac signatures in PPCM

    Time frame: At 5 years

  1250. Assessment of extracardiac signatures in PPCM

    Time frame: At 10 years

  1251. Assessment of extracardiac signatures in PPCM

    Time frame: At 15 years

  1252. Assessment of extracardiac signatures in PPCM

    Time frame: At 20 years

  1253. Assessment of extracardiac signatures in PPCM

    Time frame: At 25 years

  1254. Assessment of extracardiac signatures in PPCM

    Time frame: At 30 years

  1255. Assessment of extracardiac signatures in AFD

    Time frame: At baseline

  1256. Assessment of extracardiac signatures in AFD

    Time frame: At 5 years

  1257. Assessment of extracardiac signatures in AFD

    Time frame: At 10 years

  1258. Assessment of extracardiac signatures in AFD

    Time frame: At 15 years

  1259. Assessment of extracardiac signatures in AFD

    Time frame: At 20 years

  1260. Assessment of extracardiac signatures in AFD

    Time frame: At 25 years

  1261. Assessment of extracardiac signatures in AFD

    Time frame: At 30 years

  1262. Assessment of extracardiac signatures in storage and dysmetabolic diseases

    Time frame: At baseline

  1263. Assessment of extracardiac signatures in storage and dysmetabolic diseases

    Time frame: At 5 years

  1264. Assessment of extracardiac signatures in storage and dysmetabolic diseases

    Time frame: At 10 years

  1265. Assessment of extracardiac signatures in storage and dysmetabolic diseases

    Time frame: At 15 years

  1266. Assessment of extracardiac signatures in storage and dysmetabolic diseases

    Time frame: At 20 years

  1267. Assessment of extracardiac signatures in storage and dysmetabolic diseases

    Time frame: At 25 years

  1268. Assessment of extracardiac signatures in storage and dysmetabolic diseases

    Time frame: At 30 years

  1269. Assessment of extracardiac signatures in mitochondrial diseases

    Time frame: At baseline

  1270. Assessment of extracardiac signatures in mitochondrial diseases

    Time frame: At 5 years

  1271. Assessment of extracardiac signatures in mitochondrial diseases

    Time frame: At 10 years

  1272. Assessment of extracardiac signatures in mitochondrial diseases

    Time frame: At 15 years

  1273. Assessment of extracardiac signatures in mitochondrial diseases

    Time frame: At 20 years

  1274. Assessment of extracardiac signatures in mitochondrial diseases

    Time frame: At 25 years

  1275. Assessment of extracardiac signatures in mitochondrial diseases

    Time frame: At 30 years

  1276. Assessment of extracardiac signatures in channelopathies with structural changes

    Time frame: At baseline

  1277. Assessment of extracardiac signatures in channelopathies with structural changes

    Time frame: At 5 years

  1278. Assessment of extracardiac signatures in channelopathies with structural changes

    Time frame: At 10 years

  1279. Assessment of extracardiac signatures in channelopathies with structural changes

    Time frame: At 15 years

  1280. Assessment of extracardiac signatures in channelopathies with structural changes

    Time frame: At 20 years

  1281. Assessment of extracardiac signatures in channelopathies with structural changes

    Time frame: At 25 years

  1282. Assessment of extracardiac signatures in channelopathies with structural changes

    Time frame: At 30 years

  1283. Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1284. Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1285. Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1286. Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1287. Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1288. Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1289. Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1290. Assessment of extracardiac signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  1291. Assessment of extracardiac signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  1292. Assessment of extracardiac signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  1293. Assessment of extracardiac signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  1294. Assessment of extracardiac signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  1295. Assessment of extracardiac signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  1296. Assessment of extracardiac signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  1297. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM

    Time frame: At baseline

  1298. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM

    Time frame: At 5 years

  1299. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM

    Time frame: At 10 years

  1300. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM

    Time frame: At 15 years

  1301. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM

    Time frame: At 20 years

  1302. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM

    Time frame: At 25 years

  1303. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM

    Time frame: At 30 years

  1304. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM

    Time frame: At baseline

  1305. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM

    Time frame: At 5 years

  1306. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM

    Time frame: At 10 years

  1307. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM

    Time frame: At 15 years

  1308. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM

    Time frame: At 20 years

  1309. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM

    Time frame: At 25 years

  1310. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM

    Time frame: At 30 years

  1311. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM

    Time frame: At baseline

  1312. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM

    Time frame: At 5 years

  1313. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM

    Time frame: At 10 years

  1314. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM

    Time frame: At 15 years

  1315. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM

    Time frame: At 20 years

  1316. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM

    Time frame: At 25 years

  1317. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM

    Time frame: At 30 years

  1318. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM

    Time frame: At baseline

  1319. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM

    Time frame: At 5 years

  1320. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM

    Time frame: At 10 years

  1321. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM

    Time frame: At 15 years

  1322. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM

    Time frame: At 20 years

  1323. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM

    Time frame: At 25 years

  1324. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM

    Time frame: At 30 years

  1325. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At baseline

  1326. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 5 years

  1327. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 10 years

  1328. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 15 years

  1329. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 20 years

  1330. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 25 years

  1331. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 30 years

  1332. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1333. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1334. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1335. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1336. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1337. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1338. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1339. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  1340. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  1341. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  1342. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  1343. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  1344. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  1345. Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  1346. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM

    Time frame: At baseline

  1347. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM

    Time frame: At 5 years

  1348. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM

    Time frame: At 10 years

  1349. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM

    Time frame: At 15 years

  1350. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM

    Time frame: At 20 years

  1351. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM

    Time frame: At 25 years

  1352. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM

    Time frame: At 30 years

  1353. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM

    Time frame: At baseline

  1354. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM

    Time frame: At 5 years

  1355. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM

    Time frame: At 10 years

  1356. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM

    Time frame: At 15 years

  1357. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM

    Time frame: At 20 years

  1358. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM

    Time frame: At 25 years

  1359. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM

    Time frame: At 30 years

  1360. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM

    Time frame: At baseline

  1361. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM

    Time frame: At 5 years

  1362. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM

    Time frame: At 10 years

  1363. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM

    Time frame: At 15 years

  1364. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM

    Time frame: At 20 years

  1365. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM

    Time frame: At 25 years

  1366. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM

    Time frame: At 30 years

  1367. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM

    Time frame: At baseline

  1368. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM

    Time frame: At 5 years

  1369. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM

    Time frame: At 10 years

  1370. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM

    Time frame: At 15 years

  1371. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM

    Time frame: At 20 years

  1372. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM

    Time frame: At 25 years

  1373. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM

    Time frame: At 30 years

  1374. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC

    Time frame: At baseline

  1375. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC

    Time frame: At 5 years

  1376. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC

    Time frame: At 10 years

  1377. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC

    Time frame: At 15 years

  1378. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC

    Time frame: At 20 years

  1379. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC

    Time frame: At 25 years

  1380. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC

    Time frame: At 30 years

  1381. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP

    Time frame: At baseline

  1382. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP

    Time frame: At 5 years

  1383. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP

    Time frame: At 10 years

  1384. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP

    Time frame: At 15 years

  1385. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP

    Time frame: At 20 years

  1386. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP

    Time frame: At 25 years

  1387. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP

    Time frame: At 30 years

  1388. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM

    Time frame: At baseline

  1389. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM

    Time frame: At 5 years

  1390. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM

    Time frame: At 10 years

  1391. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM

    Time frame: At 15 years

  1392. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM

    Time frame: At 20 years

  1393. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM

    Time frame: At 25 years

  1394. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM

    Time frame: At 30 years

  1395. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD

    Time frame: At baseline

  1396. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD

    Time frame: At 5 years

  1397. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD

    Time frame: At 10 years

  1398. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD

    Time frame: At 15 years

  1399. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD

    Time frame: At 20 years

  1400. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD

    Time frame: At 25 years

  1401. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD

    Time frame: At 30 years

  1402. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At baseline

  1403. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 5 years

  1404. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 10 years

  1405. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 15 years

  1406. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 20 years

  1407. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 25 years

  1408. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: At 30 years

  1409. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1410. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1411. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1412. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1413. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1414. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1415. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1416. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  1417. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  1418. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  1419. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  1420. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  1421. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  1422. Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  1423. Assessment of prognostic signatures in DCM

    Time frame: At baseline

  1424. Assessment of prognostic signatures in DCM

    Time frame: At 5 years

  1425. Assessment of prognostic signatures in DCM

    Time frame: At 10 years

  1426. Assessment of prognostic signatures in DCM

    Time frame: At 15 years

  1427. Assessment of prognostic signatures in DCM

    Time frame: At 20 years

  1428. Assessment of prognostic signatures in DCM

    Time frame: At 25 years

  1429. Assessment of prognostic signatures in DCM

    Time frame: At 30 years

  1430. Assessment of prognostic signatures in HCM

    Time frame: At baseline

  1431. Assessment of prognostic signatures in HCM

    Time frame: At 5 years

  1432. Assessment of prognostic signatures in HCM

    Time frame: At 10 years

  1433. Assessment of prognostic signatures in HCM

    Time frame: At 15 years

  1434. Assessment of prognostic signatures in HCM

    Time frame: At 20 years

  1435. Assessment of prognostic signatures in HCM

    Time frame: At 25 years

  1436. Assessment of prognostic signatures in HCM

    Time frame: At 30 years

  1437. Assessment of prognostic signatures in RCM

    Time frame: At baseline

  1438. Assessment of prognostic signatures in RCM

    Time frame: At 5 years

  1439. Assessment of prognostic signatures in RCM

    Time frame: At 10 years

  1440. Assessment of prognostic signatures in RCM

    Time frame: At 15 years

  1441. Assessment of prognostic signatures in RCM

    Time frame: At 20 years

  1442. Assessment of prognostic signatures in RCM

    Time frame: At 25 years

  1443. Assessment of prognostic signatures in RCM

    Time frame: At 30 years

  1444. Assessment of prognostic signatures in ACM

    Time frame: At baseline

  1445. Assessment of prognostic signatures in ACM

    Time frame: At 5 years

  1446. Assessment of prognostic signatures in ACM

    Time frame: At 10 years

  1447. Assessment of prognostic signatures in ACM

    Time frame: At 15 years

  1448. Assessment of prognostic signatures in ACM

    Time frame: At 20 years

  1449. Assessment of prognostic signatures in ACM

    Time frame: At 25 years

  1450. Assessment of prognostic signatures in ACM

    Time frame: At 30 years

  1451. Assessment of prognostic signatures in LVNC

    Time frame: At baseline

  1452. Assessment of prognostic signatures in LVNC

    Time frame: At 5 years

  1453. Assessment of prognostic signatures in LVNC

    Time frame: At 10 years

  1454. Assessment of prognostic signatures in LVNC

    Time frame: At 15 years

  1455. Assessment of prognostic signatures in LVNC

    Time frame: At 20 years

  1456. Assessment of prognostic signatures in LVNC

    Time frame: At 25 years

  1457. Assessment of prognostic signatures in LVNC

    Time frame: At 30 years

  1458. Assessment of prognostic signatures in AMVP

    Time frame: At baseline

  1459. Assessment of prognostic signatures in AMVP

    Time frame: At 5 years

  1460. Assessment of prognostic signatures in AMVP

    Time frame: At 10 years

  1461. Assessment of prognostic signatures in AMVP

    Time frame: At 15 years

  1462. Assessment of prognostic signatures in AMVP

    Time frame: At 20 years

  1463. Assessment of prognostic signatures in AMVP

    Time frame: At 25 years

  1464. Assessment of prognostic signatures in AMVP

    Time frame: At 30 years

  1465. Assessment of prognostic signatures in PPCM

    Time frame: At baseline

  1466. Assessment of prognostic signatures in PPCM

    Time frame: At 5 years

  1467. Assessment of prognostic signatures in PPCM

    Time frame: At 10 years

  1468. Assessment of prognostic signatures in PPCM

    Time frame: At 15 years

  1469. Assessment of prognostic signatures in PPCM

    Time frame: At 20 years

  1470. Assessment of prognostic signatures in PPCM

    Time frame: At 25 years

  1471. Assessment of prognostic signatures in PPCM

    Time frame: At 30 years

  1472. Assessment of prognostic signatures in AFD

    Time frame: At baseline

  1473. Assessment of prognostic signatures in AFD

    Time frame: At 5 years

  1474. Assessment of prognostic signatures in AFD

    Time frame: At 10 years

  1475. Assessment of prognostic signatures in AFD

    Time frame: At 15 years

  1476. Assessment of prognostic signatures in AFD

    Time frame: At 20 years

  1477. Assessment of prognostic signatures in AFD

    Time frame: At 25 years

  1478. Assessment of prognostic signatures in AFD

    Time frame: At 30 years

  1479. Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1480. Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1481. Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1482. Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1483. Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1484. Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1485. Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1486. Assessment of prognostic signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  1487. Assessment of prognostic signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  1488. Assessment of prognostic signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  1489. Assessment of prognostic signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  1490. Assessment of prognostic signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  1491. Assessment of prognostic signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  1492. Assessment of prognostic signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  1493. Assessment of response to treatment signatures in DCM

    Time frame: At baseline

  1494. Assessment of response to treatment signatures in DCM

    Time frame: At 5 years

  1495. Assessment of response to treatment signatures in DCM

    Time frame: At 10 years

  1496. Assessment of response to treatment signatures in DCM

    Time frame: At 15 years

  1497. Assessment of response to treatment signatures in DCM

    Time frame: At 20 years

  1498. Assessment of response to treatment signatures in DCM

    Time frame: At 25 years

  1499. Assessment of response to treatment signatures in DCM

    Time frame: At 30 years

  1500. Assessment of response to treatment signatures in HCM

    Time frame: At baseline

  1501. Assessment of response to treatment signatures in HCM

    Time frame: At 5 years

  1502. Assessment of response to treatment signatures in HCM

    Time frame: At 10 years

  1503. Assessment of response to treatment signatures in HCM

    Time frame: At 15 years

  1504. Assessment of response to treatment signatures in HCM

    Time frame: At 20 years

  1505. Assessment of response to treatment signatures in HCM

    Time frame: At 25 years

  1506. Assessment of response to treatment signatures in HCM

    Time frame: At 30 years

  1507. Assessment of response to treatment signatures in RCM

    Time frame: At baseline

  1508. Assessment of response to treatment signatures in RCM

    Time frame: At 5 years

  1509. Assessment of response to treatment signatures in RCM

    Time frame: At 10 years

  1510. Assessment of response to treatment signatures in RCM

    Time frame: At 15 years

  1511. Assessment of response to treatment signatures in RCM

    Time frame: At 20 years

  1512. Assessment of response to treatment signatures in RCM

    Time frame: At 25 years

  1513. Assessment of response to treatment signatures in RCM

    Time frame: At 30 years

  1514. Assessment of response to treatment signatures in ACM

    Time frame: At baseline

  1515. Assessment of response to treatment signatures in ACM

    Time frame: At 5 years

  1516. Assessment of response to treatment signatures in ACM

    Time frame: At 10 years

  1517. Assessment of response to treatment signatures in ACM

    Time frame: At 15 years

  1518. Assessment of response to treatment signatures in ACM

    Time frame: At 20 years

  1519. Assessment of response to treatment signatures in ACM

    Time frame: At 25 years

  1520. Assessment of response to treatment signatures in ACM

    Time frame: At 30 years

  1521. Assessment of response to treatment signatures in LVNC

    Time frame: At baseline

  1522. Assessment of response to treatment signatures in LVNC

    Time frame: At 5 years

  1523. Assessment of response to treatment signatures in LVNC

    Time frame: At 10 years

  1524. Assessment of response to treatment signatures in LVNC

    Time frame: At 15 years

  1525. Assessment of response to treatment signatures in LVNC

    Time frame: At 20 years

  1526. Assessment of response to treatment signatures in LVNC

    Time frame: At 25 years

  1527. Assessment of response to treatment signatures in LVNC

    Time frame: At 30 years

  1528. Assessment of response to treatment signatures in AMVP

    Time frame: At baseline

  1529. Assessment of response to treatment signatures in AMVP

    Time frame: At 5 years

  1530. Assessment of response to treatment signatures in AMVP

    Time frame: At 10 years

  1531. Assessment of response to treatment signatures in AMVP

    Time frame: At 15 years

  1532. Assessment of response to treatment signatures in AMVP

    Time frame: At 20 years

  1533. Assessment of response to treatment signatures in AMVP

    Time frame: At 25 years

  1534. Assessment of response to treatment signatures in AMVP

    Time frame: At 30 years

  1535. Assessment of response to treatment signatures in PPCM

    Time frame: At baseline

  1536. Assessment of response to treatment signatures in PPCM

    Time frame: At 5 years

  1537. Assessment of response to treatment signatures in PPCM

    Time frame: At 10 years

  1538. Assessment of response to treatment signatures in PPCM

    Time frame: At 15 years

  1539. Assessment of response to treatment signatures in PPCM

    Time frame: At 20 years

  1540. Assessment of response to treatment signatures in PPCM

    Time frame: At 25 years

  1541. Assessment of response to treatment signatures in PPCM

    Time frame: At 30 years

  1542. Assessment of response to treatment signatures in AFD

    Time frame: At baseline

  1543. Assessment of response to treatment signatures in AFD

    Time frame: At 5 years

  1544. Assessment of response to treatment signatures in AFD

    Time frame: At 10 years

  1545. Assessment of response to treatment signatures in AFD

    Time frame: At 15 years

  1546. Assessment of response to treatment signatures in AFD

    Time frame: At 20 years

  1547. Assessment of response to treatment signatures in AFD

    Time frame: At 25 years

  1548. Assessment of response to treatment signatures in AFD

    Time frame: At 30 years

  1549. Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

  1550. Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

  1551. Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

  1552. Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

  1553. Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

  1554. Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

  1555. Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

  1556. Assessment of response to treatment signatures in overlapping and undefined phenotypes

    Time frame: At baseline

  1557. Assessment of response to treatment signatures in overlapping and undefined phenotypes

    Time frame: At 5 years

  1558. Assessment of response to treatment signatures in overlapping and undefined phenotypes

    Time frame: At 10 years

  1559. Assessment of response to treatment signatures in overlapping and undefined phenotypes

    Time frame: At 15 years

  1560. Assessment of response to treatment signatures in overlapping and undefined phenotypes

    Time frame: At 20 years

  1561. Assessment of response to treatment signatures in overlapping and undefined phenotypes

    Time frame: At 25 years

  1562. Assessment of response to treatment signatures in overlapping and undefined phenotypes

    Time frame: At 30 years

  1563. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1564. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1565. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1566. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1567. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1568. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1569. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1570. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1571. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1572. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1573. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1574. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1575. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1576. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1577. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1578. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1579. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1580. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1581. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1582. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1583. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1584. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1585. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1586. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1587. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1588. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1589. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1590. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1591. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1592. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1593. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1594. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1595. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1596. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1597. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1598. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1599. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1600. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1601. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1602. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1603. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1604. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1605. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1606. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1607. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1608. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1609. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1610. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1611. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1612. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1613. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1614. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1615. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1616. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1617. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1618. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1619. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1620. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1621. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1622. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1623. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1624. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1625. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1626. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1627. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1628. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1629. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1630. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1631. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1632. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1633. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1634. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1635. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1636. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1637. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1638. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1639. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1640. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At baseline

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1641. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 5 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1642. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 10 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1643. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 15 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1644. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 20 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1645. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 25 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1646. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: At 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1647. Evaluation of efficacy of pharmacological antiarrhythmic treatment on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1648. Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in overlapping and undefined phenotypes Efficacy of pharmacological antiarrhythmic treatment on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1649. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in DCM

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1650. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in HCM

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1651. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in RCM

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1652. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in ACM

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1653. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in LVNC

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1654. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AMVP

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1655. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in PPCM

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1656. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AFD

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1657. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1658. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1659. Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in overlapping and undefined phenotypes

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1660. Identification of criteria for device implants (PM, ICD, S-ICD, CRT-D...) in NICMs patients

    Time frame: By 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  1661. Identification of the most suitable therapeutic strategies based on indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes

    Time frame: By 30 years

    This applies to NICM patients with supraventricular arrhythmias, bradyarrhythmias, or ventricular arrhythmias, with or without M-Inf.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  1662. Identification of the best candidates to multidisciplinary management of NICMs

    Time frame: By 30 years

    by identification of the subgroups of patients showing the maximal effects (i.e. lowest incidence of major and minor adverse events) and the minimal risks (i.e. lowest incidence of side effects) following application of multidisciplinary care.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  1663. Indication and timing for device (ICD, CRT-D) implant in primary prevention, based on multidisciplinary, multimodal, multiparametric risk assessment in NICMs, and in relation to different general and etiology-dependent treatments

    Time frame: By 30 years

    by identification of the subgroups of patients showing the maximal effects (i.e. lowest incidence of major and minor adverse events) and the minimal risks (i.e. lowest incidence of side effects) following application of multidisciplinary care.

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  1664. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in DCM patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1665. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in HCM patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1666. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in RCM patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1667. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in ACM patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1668. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in LVNC patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1669. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in PPCM patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1670. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AMVP patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1671. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AFD patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1672. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in storage and dysmetabolic diseases patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1673. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in mitochondrial diseases patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1674. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in channelopathies with structural changes patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1675. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1676. Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with overlapping and undefined phenotypes patients, i.e. effects on major and minor events

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1677. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in DCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1678. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in HCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1679. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in RCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1680. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in ACM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1681. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in LVNC patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1682. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AMVP patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1683. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in PPCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1684. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AFD patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1685. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in storage and dysmetabolic diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1686. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in mitochondrial diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1687. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in channelopathies with structural change patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1688. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, , i.e. effects on major and minor events

    Time frame: By 30 years

    Analysis of safety, i.e. incidence of adverse reactions.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1689. Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in overlapping and undefined phenotypes patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1690. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1691. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1692. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1693. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1694. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1695. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1696. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1697. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1698. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1699. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1700. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in channelopathies with structural changes i.e. effects on major and minor events.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes).

    Analysis of safety, i.e. incidence of adverse reactions.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1701. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes).

    Analysis of safety, i.e. incidence of adverse reactions.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1702. Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in overlapping and undefined phenotypes i.e. effects on major and minor events.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes).

    Analysis of safety, i.e. incidence of adverse reactions.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1703. Efficacy of etiology -specific treatments, including those aimed to target extra - cardiac disease manifestations in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1704. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1705. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1706. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1707. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1708. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1709. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1710. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1711. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1712. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1713. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1714. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes) Analysis of safety, i.e. incidence of adverse reactions.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1715. Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1716. Efficacy of replacement therapy, molecular therapy, gene therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1717. Efficacy of replacement therapy, molecular therapy, gene therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1718. Efficacy of replacement therapy, molecular therapy, gene therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1719. Efficacy of replacement therapy, molecular therapy, gene therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1720. Efficacy of replacement therapy, molecular therapy, gene therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1721. Efficacy of replacement therapy, molecular therapy, gene therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1722. Efficacy of replacement therapy, molecular therapy, gene therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1723. Efficacy of replacement therapy, molecular therapy, gene therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1724. Efficacy of replacement therapy, molecular therapy, gene therapy in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1725. Efficacy of replacement therapy, molecular therapy, gene therapy in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1726. Efficacy of replacement therapy, molecular therapy, gene therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1727. Efficacy of replacement therapy, molecular therapy, gene therapy in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1728. Efficacy of heart transplantation and other treatment for end-stage heart failure in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1729. Efficacy of heart transplantation and other treatment for end-stage heart failure in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1730. Efficacy of heart transplantation and other treatment for end-stage heart failure in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1731. Efficacy of heart transplantation and other treatment for end-stage heart failure in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1732. Efficacy of heart transplantation and other treatment for end-stage heart failure in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1733. Efficacy of heart transplantation and other treatment for end-stage heart failure in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1734. Efficacy of heart transplantation and other treatment for end-stage heart failure in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1735. Efficacy of heart transplantation and other treatment for end-stage heart failure in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1736. Efficacy of heart transplantation and other treatment for end-stage heart failure in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1737. Efficacy of heart transplantation and other treatment for end-stage heart failure in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1738. Efficacy of heart transplantation and other treatment for end-stage heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.

    Time frame: By 30 years

    Analysis of safety, i.e. incidence of adverse reactions.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1739. Efficacy of heart transplantation and other treatment for end-stage heart failure in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1740. Efficacy of surgical or hemodynamic procedures in DCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1741. Efficacy of surgical or hemodynamic procedures in HCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1742. Efficacy of surgical or hemodynamic procedures in RCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1743. Efficacy of surgical or hemodynamic procedures in ACM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1744. Efficacy of surgical or hemodynamic procedures in LVNC, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1745. Efficacy of surgical or hemodynamic procedures in AMVP, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1746. Efficacy of surgical or hemodynamic procedures in PPCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1747. Efficacy of surgical or hemodynamic procedures in AFD, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1748. Efficacy of surgical or hemodynamic procedures in storage and dysmetabolic diseases, mitochondrial diseases, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1749. Efficacy of surgical or hemodynamic procedures in channelopathies with structural changes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1750. Efficacy of surgical or hemodynamic procedures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, i.e. effects on major and minor event i.e. effects on major and minor events.

    Time frame: By 30 years

    Analysis of safety, i.e. incidence of adverse reactions.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1751. Efficacy of surgical or hemodynamic procedures in overlapping and undefined phenotypes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1752. Investigation of cardiac device implant in primary and secondary prevention, in all patients, as well as in subgroups with and without M-Infl in NICMs

    Time frame: By 30 years

    (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes)

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  1753. Investigation of ablation of cardiac arrhythmias (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes) in NICMs

    Time frame: By 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  1754. Role of ablation (any technique) on arrhythmic outcomes in NICMs, in all patients, as well as in subgroups with and without arrhythmias and MInfl

    Time frame: By 30 years

    NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, toxic, dysmetabolic, mitochondrial, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

  1755. Indications and optimal timing for any electrophysiological or interventional procedures in HCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1756. Indications and optimal timing for any electrophysiological or interventional procedures in ACM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1757. Indications and optimal timing for any electrophysiological or interventional procedures in LVNC, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1758. Indications and optimal timing for any electrophysiological or interventional procedures in AMVP, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1759. Indications and optimal timing for any electrophysiological or interventional procedures in PPCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1760. Indications and optimal timing for any electrophysiological or interventional procedures in AFD, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1761. Indications and optimal timing for any electrophysiological or interventional procedures in storage and dysmetabolic diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1762. Indications and optimal timing for any electrophysiological or interventional procedures in mitochondrial diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1763. Indications and optimal timing for any electrophysiological or interventional procedures in channelopathies with structural changes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1764. Indications and optimal timing for any electrophysiological or interventional procedures rheumatologic or neuromuscular diseases

    Time frame: By 30 years

    i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings.

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

  1765. Indications and optimal timing for any electrophysiological or interventional procedures in overlapping and undefined phenotypes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings

    Time frame: By 30 years

    Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.

    Minor events: non-sustained ventricular arrhythmias, supraventricular arrhythmias, other bradyarrhythmias, any structural/functional myocardial abnormality detectable by multimodal diagnostic workup, abnormal laboratory, tissue or multiomic biomarkers, all-cause hospitalizations, disease costs, complications related to disease management, extra-cardiac disease-related non-fatal endpoints.

Study contacts

Contact information is provided by the study sponsor or research team.

Giovanni Peretto, MD

CONTACT

[email protected]

+39 0226437482

Simone Sala, MD

CONTACT

[email protected]

+39 0226437483

Sponsors and collaborators

Lead sponsor

Scientific Institute San Raffaele

Other

Registry information

Acronym: AINICM

Important dates

Study start
2018
Primary completion
2035
Study completion
2035
First posted
Sep 23, 2024
Registry last updated
Sep 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.